<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title>PLoS ONE</journal-title><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">08-PONE-RA-03389R2</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0002533</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Genetics and Genomics/Complex Traits</subject><subject>Genetics and Genomics/Genetics of Disease</subject><subject>Cardiovascular Disorders/Coronary Artery Disease</subject><subject>Cardiovascular Disorders/Myocardial Infarction</subject></subj-group></article-categories><title-group><article-title>The M235T Polymorphism in the <italic>AGT</italic> Gene and CHD Risk: Evidence of a Hardy-Weinberg Equilibrium Violation and Publication Bias in a Meta-Analysis</article-title><alt-title alt-title-type="running-head">AGT M235T Variant and CHD</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zafarmand</surname><given-names>Mohammad Hadi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>van der Schouw</surname><given-names>Yvonne T.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Grobbee</surname><given-names>Diederick E.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>de Leeuw</surname><given-names>Peter W.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bots</surname><given-names>Michiel L.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Persian Gulf Health Research Center, Bushehr University of Medical Sciences and Health Services, Bushehr, Iran</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Department of Internal Medicine, University Hospital Maastricht, Maastricht, The Netherlands</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Kronenberg</surname><given-names>Florian</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Innsbruck Medical University, Austria</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>m.l.bots@umcutrecht.nl</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: MZ MB Yv DG. Performed the experiments: Pd Yv. Analyzed the data: MZ MB. Contributed reagents/materials/analysis tools: MZ MB. Wrote the paper: MZ MB Pd Yv DG.</p></fn></author-notes><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>25</day><month>6</month><year>2008</year></pub-date><volume>3</volume><issue>6</issue><elocation-id>e2533</elocation-id><history><date date-type="received"><day>23</day><month>1</month><year>2008</year></date><date date-type="accepted"><day>30</day><month>5</month><year>2008</year></date></history><copyright-statement>Zafarmand et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2008</copyright-year><abstract><sec><title>Background</title><p>The M235T polymorphism in the <italic>AGT</italic> gene has been related to an increased risk of hypertension. This finding may also suggest an increased risk of coronary heart disease (CHD).</p></sec><sec><title>Methodology/Principal Findings</title><p>A case-cohort study was conducted in 1,732 unrelated middle-age women (210 CHD cases and 1,522 controls) from a prospective cohort of 15,236 initially healthy Dutch women. We applied a Cox proportional hazards model to study the association of the polymorphism with acute myocardial infarction (AMI) (n&#x0200a;&#x0003d;&#x0200a;71) and CHD. In the case-cohort study, no increased risk for CHD was found under the additive genetic model (hazard ratio &#x0005b;HR&#x0005d;&#x0200a;&#x0003d;&#x0200a;1.20; 95&#x00025; confidence interval &#x0005b;CI&#x0005d;, 0.86 to 1.68; <italic>P</italic>&#x0200a;&#x0003d;&#x0200a;<italic>0.28</italic>). This result was not changed by adjustment (HR&#x0200a;&#x0003d;&#x0200a;1.17; 95&#x00025; CI, 0.83 to 1.64; <italic>P</italic>&#x0200a;&#x0003d;&#x0200a;<italic>0.38</italic>) nor by using dominant, recessive and pairwise genetic models. Analyses for AMI risk under the additive genetic model also did not show any statistically significant association (crude HR&#x0200a;&#x0003d;&#x0200a;1.14; 95&#x00025; CI, 0.93 to 1.39; <italic>P</italic>&#x0200a;&#x0003d;&#x0200a;<italic>0.20</italic>). To evaluate the association, a comprehensive systematic review and meta-analysis were undertaken of all studies published up to February 2007 (searched through PubMed/MEDLINE, Web of Science and EMBASE). The meta-analysis (38 studies with 13284 cases and 18722 controls) showed a per-allele odds ratio (OR) of 1.08 (95&#x00025; CI, 1.01 to 1.15; <italic>P</italic>&#x0200a;&#x0003d;&#x0200a;<italic>0.02</italic>). Moderate to large levels of heterogeneity were identified between studies. Hardy-Weinberg equilibrium (HWE) violation and the mean age of cases were statistically significant sources of the observed variation. In a stratum of non-HWE violation studies, there was no effect. An asymmetric funnel plot, the Egger's test (<italic>P</italic>&#x0200a;&#x0003d;&#x0200a;0.066), and the Begg-Mazumdar test (<italic>P</italic>&#x0200a;&#x0003d;&#x0200a;0.074) were all suggestive of the presence of publication bias.</p></sec><sec><title>Conclusions/Significance</title><p>The pooled OR of the present meta-analysis, including our own data, presented evidence that there is an increase in the risk of CHD conferred by the M235T variant of the <italic>AGT</italic> gene. However, the relevance of this weakly positive overall association remains uncertain because it may be due to various residual biases, including HWE-violation and publication biases.</p></sec></abstract><counts><page-count count="16"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Angiotensinogen (AGT) is a liver protein that interacts with renin to produce angiotensin I, the pro-hormone of angiotensin II. Angiotensin II is the major effector molecule of the renin-angiotensin-aldosterone system (RAAS) and plays a key role in the regulation of blood pressure (BP) by increasing vascular tone and promoting sodium retention. Genetic variants in the angiotensinogen gene modify the plasma concentration of angiotensinogen, which has been directly related to arterial blood pressure <xref ref-type="bibr" rid="pone.0002533-Jeunemaitre1">&#x0005b;1&#x0005d;</xref>. The molecular variant (M235T) of the <italic>AGT</italic> gene, encoding a threonine instead of a methionine at residue 235 of the mature protein, has been associated with a higher plasma AGT level and higher BP in patients homozygous for the T allele and occurs among various ethnic populations <xref ref-type="bibr" rid="pone.0002533-Jeunemaitre1">&#x0005b;1&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0002533-Paillard1">&#x0005b;3&#x0005d;</xref>. In a meta-analysis, the TT genotype was associated with a 32&#x00025; increase in the risk of hypertension in white people but not in non-white people, when compared with the MM genotype <xref ref-type="bibr" rid="pone.0002533-Staessen1">&#x0005b;4&#x0005d;</xref>.</p><p>Given the importance of hypertension in the occurrence of coronary heart disease <xref ref-type="bibr" rid="pone.0002533-Sattar1">&#x0005b;5&#x0005d;</xref>, this finding suggests that this polymorphism may be related to increased risk of CHD. A few studies <xref ref-type="bibr" rid="pone.0002533-Ludwig1">&#x0005b;6&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0002533-RodriguezPerez1">&#x0005b;8&#x0005d;</xref>, including recent publications, <xref ref-type="bibr" rid="pone.0002533-Lanz1">&#x0005b;9&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Sekuri1">&#x0005b;10&#x0005d;</xref> have found that there is an association of the M235T <italic>AGT</italic> variant with increased CHD risk; however, this relationship was not confirmed in several other studies <xref ref-type="bibr" rid="pone.0002533-Nair1">&#x0005b;11&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0002533-Tiret1">&#x0005b;13&#x0005d;</xref> as well as in a meta-analysis <xref ref-type="bibr" rid="pone.0002533-Sethi2">&#x0005b;14&#x0005d;</xref>. Marked ethnic differences in the frequency of the T allele, small sample sizes and genotyping or phenotyping errors could partly account for discrepancies among these gene-disease association studies. Therefore, we investigated the association of the M235T polymorphism in the <italic>AGT</italic> gene (National Center for Biotechnology Information single nucleotide polymorphism cluster ID rs699) with acute myocardial infarction (AMI) and CHD in a large population-based cohort of middle-aged Dutch women and conducted an updated meta-analysis of the available studies to clarify the role of the M235T polymorphism in CHD risk.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2a"><title>Case-cohort study</title><p>Study design, general questionnaire, anthropometric and laboratory measurements have been described in detail elsewhere <xref ref-type="bibr" rid="pone.0002533-Boker1">&#x0005b;15&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0002533-Zafarmand1">&#x0005b;16&#x0005d;</xref>. Briefly, the study population consisted of participants of the Prospect-EPIC cohort. Participants were recruited between 1993 and 1997 among women living in Utrecht and the vicinity who attended the regional population-based breast cancer-screening program. A total of 17,357 women, aged 49&#x02013;70, were included. At baseline, a general and a dietary questionnaire were administered, a limited physical examination was performed and a non-fasting blood sample was taken. Follow-up event information was obtained from the Dutch Centre for Health Care Information, which holds a standardized computerized register of hospital discharge diagnoses. Using the International Classification of Diseases, ninth Revision (ICD-9) codes for the main discharge reason, we categorized cardiovascular disease (codes 390&#x02013;459) as CHD (codes 410&#x02013;414), including AMI (code 410), and other cardiovascular diseases. Whenever multiple events (AMI and CHD) occurred, the first occurrence of that endpoint was taken as the endpoint of interest in endpoint-specific analyses. All women signed an informed consent form prior to study inclusion. The study was approved by the Institutional Review Board of the University Medical Center Utrecht.</p><p>We applied the case-cohort design introduced by Prentice <xref ref-type="bibr" rid="pone.0002533-Prentice1">&#x0005b;17&#x0005d;</xref>. From the 17,357 women in the total cohort, we randomly selected a sample of 10&#x00025; as the sub-cohort (n&#x0200a;&#x0003d;&#x0200a;l736). Women who did not consent to linkage with vital status registries or who were not traceable (cases n&#x0200a;&#x0003d;&#x0200a;3/sub-cohort n&#x0200a;&#x0003d;&#x0200a;38) were not included. Women who reported a diagnosis of cardiovascular disease (ICD-9; 390&#x02013;459) at baseline or who had missing questionnaires, blood, or DNA samples were excluded. This resulted in 15,236 women in the total cohort and 1522 women in the sub-cohort (as the control group) at baseline. All individuals with first fatal and non-fatal CHD and ischemic stroke events that arose during follow-up until January 1<sup>st</sup> 2000 were selected as cases. These were 211 CHD cases, including 71 AMIs. For all case subjects, follow-up ended at the date of diagnosis or at the date of death due to cardiovascular disease.</p><sec id="s2a1"><title>Genetic analysis</title><p>Genetic analysis was performed at the Cardiovascular Genotyping (CAGT) laboratory of the Department of Internal Medicine of the University Hospital Maastricht. Genomic DNA was extracted from buffy coats using the QIAamp&#x000ae; Blood Kit (Qiagen Inc., Valencia, California, USA). Genotyping of the polymorphisms was performed using a multilocus genotyping assay for candidate markers of cardiovascular disease risk (Roche Molecular Systems Inc., Pleasanton, CA, USA) <xref ref-type="bibr" rid="pone.0002533-Cheng1">&#x0005b;18&#x0005d;</xref>. Briefly, each DNA sample was amplified using two multiplex polymerase chain reactions, and the alleles were genotyped simultaneously using an array of immobilized sequence-specific oligonucleotide probes. This array of probes was blotted on plastic strips, and, after staining, genotypes were scored based on blue (positive) and white (negative) bands. Each blue band, representing a specific genotype, was scored by specific software (counting the pixel intensity of each band) and checked manually. Genotyping was performed blinded to the case-control status. A random double-check was performed to detect potential genotyping errors in a subset of 100 samples. The check confirmed the previous genotyping results by 100&#x00025;.</p></sec><sec id="s2a2"><title>Data analysis</title><p>Hardy-Weinberg equilibrium (HWE) was tested with the &#x003c7;<sup>2</sup> test among the controls. Allele frequencies were estimated by gene counting. We used the ANOVA <italic>F</italic> test to estimate relationships among the M235T genotypes and continuous variables, while we tested the significance of any difference in proportions by applying the &#x003c7;<sup>2</sup> statistic. A p-value &#x0003c;0.05 (2-sided) was considered statistically significant.</p><p>To assess the relationship of the M235T polymorphism in the <italic>AGT</italic> gene with the outcome, we used a Cox proportional hazards model with an estimation procedure adapted for case-cohort designs. We used the unweighted method by Prentice <xref ref-type="bibr" rid="pone.0002533-Prentice1">&#x0005b;17&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-OnlandMoret1">&#x0005b;19&#x0005d;</xref>, which is incorporated in a SAS macro at <ext-link ext-link-type="uri" xlink:href="http://lib.stat.cmu.edu/general/robphreg">http://lib.stat.cmu.edu/general/robphreg</ext-link>. A previous meta-analysis <xref ref-type="bibr" rid="pone.0002533-Sethi2">&#x0005b;14&#x0005d;</xref> showed that the effect of the <italic>AGT</italic> M235T variant on its intermediate phenotype (plasma angiotensinogen level) follows an additive model according to the number of T alleles &#x0005b;5&#x00025; (95&#x00025; CI: 2 to 8&#x00025;) increase for the MT and 11&#x00025; (95&#x00025; CI: 7 to 15&#x00025;) increase for the TT genotype versus the MM genotype&#x0005d;. Therefore, our <italic>priori</italic> hypothesis was that the association between the M235T polymorphism in the <italic>AGT</italic> gene and CHD follows an additive model according to the number of T alleles. However, other genetic models were evaluated as well. We considered different modes of inheritance as follows: <italic>the additive &#x0201c;per-allele&#x0201d; model</italic>, the T allele was compared between cases and controls by assigning scores of 0, 1, and 2 to homozygotes for the M allele, heterozygotes, and homozygotes for the T allele, respectively; <italic>the recessive model</italic>, the TT genotype versus the MT and MM combined genotypes; and <italic>the dominant model</italic>, the MT and TT genotypes combined versus the MM genotype. We also performed separate pairwise comparisons of the MT and TT genotypes versus the MM genotype.</p></sec></sec><sec id="s2b"><title>Meta-analysis</title><sec id="s2b1"><title>Searching</title><p>We searched PubMed/MEDLINE, Web of Science, and EMBASE up to February 2007 for observational studies evaluating an association between the M235T polymorphism in the <italic>AGT</italic> gene and CHD. Terms used for the search contained both medical subject heading terms and text words: (Met235Thr OR M235T OR T704C) AND (angiotensinogen OR <italic>AGT</italic>) AND (polymorphism OR mutation OR genetic OR genotype) AND (&#x0201c;coronary disease&#x0201d; OR &#x0201c;coronary heart disease&#x0201d; OR CHD OR &#x0201c;myocardial infarction&#x0201d; OR MI OR &#x0201c;myocardial infarct&#x0201d; OR &#x0201c;coronary artery disease&#x0201d; OR CAD OR &#x0201c;ischemic heart disease&#x0201d; OR IHD OR &#x0201c;cardiovascular disease&#x0201d; OR &#x0201c;heart disease&#x0201d; OR angina). We also retrieved additional studies by hand searching the bibliographies of original research reports and review articles and through the MEDLINE option &#x0201c;related articles&#x0201d;. Search results were limited to articles published in English and studies on human subjects.</p></sec><sec id="s2b2"><title>Selection</title><p>All studies were considered potentially eligible if they aimed to investigate the relationship between the M235T genotypes and risk of CHD or MI. Any observational study, regardless of sample size, which fulfilled the following criteria, was included: (i) <italic>AGT</italic> M235T genotype frequencies were provided by case-control status (studies without controls were excluded); (ii) risk of CHD or MI was evaluated (studies on recurrent coronary events were excluded); (iii) relevant data were presented to calculate the effect size and its 95&#x00025; CI; (iv) non-overlapping data were contained. For duplicate publications, the study with the smaller data set was excluded.</p></sec><sec id="s2b3"><title>Data abstraction</title><p>The following information was extracted from each study that we included: the first author's name; country; year of publication; the population evaluated; study design; mean age or age range for case-patients and controls; definition and number of cases and controls; allele frequencies and genotype distribution in case-patients and controls (where data were not given, they were calculated from the corresponding genotyping frequencies of the case and control groups); consistency of genotype frequencies with HWE (calculated); gender in the evaluated population and male percentage, matching variables, use of blinding of genotyping staff, performing regenotyping of a random sample, and crude ORs and 95&#x00025; CIs for development of CHD or MI related to the <italic>AGT</italic> gene genotypes based on different genetic models (from the original paper or calculated from crude data if not provided). We again considered a dominant, a recessive, an additive &#x0201c;per-allele&#x0201d; model and pairwise comparisons. Data were extracted independently and entered into separate databases by two authors (performed by MHZ and MLB). Results were compared, and disagreements were resolved by a consensus.</p></sec><sec id="s2b4"><title>Quantitative data synthesis</title><p>The method of Mantel-Haenszel was used to calculate the odds ratio for the pooled data in a fixed-effects model, and, if there was evidence for heterogeneity, the DerSimonian-Laird method was used for the pooled odds ratio in a random-effects model, under pairwise comparisons of the different genotypes and dominant, recessive, and additive inheritance models. For all the models used, the T allele was considered the risk allele. The genetic model to be considered as the <italic>priori</italic> hypothesis was the additive model. In each study, we tested for HWE by using the &#x003c7;<sup>2</sup> test or an exact test among the controls by using the genhwi command in Stata 9.2 <xref ref-type="bibr" rid="pone.0002533-Trikalinos1">&#x0005b;20&#x0005d;</xref>.</p><p>In addition, we used Cochran's &#x003c7;<sup>2</sup> &#x02013; based <bold><italic>Q</italic></bold> statistic for between-study heterogeneity, which is considered to be significant for <italic>P</italic>&#x0003c;0.10, as well as the <bold><italic>I<sup>2</sup></italic></bold> statistic for estimation of inconsistency in meta-analyses <xref ref-type="bibr" rid="pone.0002533-Trikalinos1">&#x0005b;20&#x0005d;</xref>. <bold><italic>I<sup>2</sup></italic></bold> represents the percentage of the observed between-study variability due to heterogeneity rather than to chance. It ranges between 0&#x00025; and 100&#x00025;, where a value of 0&#x00025; indicates no observed heterogeneity, and larger values indicate an increasing degree of heterogeneity (roughly suggested cut-off points include: <bold><italic>I<sup>2</sup></italic></bold>&#x0200a;&#x0003d;&#x0200a;0&#x02013;25&#x00025;, no heterogeneity; <bold><italic>I<sup>2</sup></italic></bold>&#x0200a;&#x0003d;&#x0200a;25&#x02013;50&#x00025;, moderate heterogeneity; <bold><italic>I<sup>2</sup></italic></bold>&#x0200a;&#x0003d;&#x0200a;50&#x02013;75&#x00025;, large heterogeneity; <bold><italic>I<sup>2</sup></italic></bold>&#x0200a;&#x0003d;&#x0200a;75&#x02013;100&#x00025;, extreme heterogeneity) <xref ref-type="bibr" rid="pone.0002533-Higgins1">&#x0005b;21&#x0005d;</xref>.</p><p>We used funnel plots to examine the publication bias of reported associations. We also used Egger's test and the Begg-Mazumdar test with 95&#x00025; CI for evaluation of publication bias, which are considered to be significant for <italic>P</italic>&#x0003c;0.10. Meta-analysis was carried out using STATA 9.2. We used random effect meta-regression models with restricted maximum likelihood estimation to evaluate the extent to which different variables explained heterogeneity among the individual ORs. The pre-specified characteristics for assessment of sources of inter-study heterogeneity were: study size (for detailed definition see <xref ref-type="bibr" rid="pone.0002533-AgerholmLarsen1">&#x0005b;22&#x0005d;</xref>); ethnicity of population evaluated (of Caucasian descent, East Asian, and others); male percentage in each study, matching (matched or unmatched); blinding of genotyping staff (blinded, or not reported); performing regenotyping of a random sample (performed or not reported); violating HWE (violated or confirmed; the term &#x0201c;violated&#x0201d; used for statistically significant deviation of HWE) in sub-group analysis as well as in meta-regression analysis.</p></sec><sec id="s2b5"><title>HWE Correction</title><p>For evaluating the impact of HWE-violated studies on effect estimates (at the 0.05 significance level) under different genetic models, odds ratios, and variances were corrected by using the HWE-predicted genotype counts in the control instead of the observed counts as previously suggested <xref ref-type="bibr" rid="pone.0002533-Trikalinos1">&#x0005b;20&#x0005d;</xref>. Thereafter, they were included in the sensitivity analysis.</p></sec></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Prospect-EPIC study results</title><p>The general characteristics of the randomly sampled participants of the cohort (N&#x0200a;&#x0003d;&#x0200a;1522) are given in <xref ref-type="table" rid="pone-0002533-t001">Table 1</xref>. The genotype distribution was in Hardy-Weinberg equilibrium (&#x003c7;<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;<italic>0.020</italic>; <italic>P</italic>&#x0200a;&#x0003d;&#x0200a;<italic>0.89</italic>). General and clinical characteristics of CHD cases and controls are shown in <xref ref-type="table" rid="pone-0002533-t001">Table 1</xref>. The median follow up time for the random sample was 4.3 years, with a total of 6,523 person years. The actual follow-up in the baseline cohort of 15,236 women was 64,768 person years. Due to the case-cohort design, 23 women in the sub-cohort eventually were CHD cases (among which there were nine AMI cases).</p><table-wrap id="pone-0002533-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002533.t001</object-id><label>Table 1</label><caption><title>Baseline characteristics of the sub-cohort according to genotype, and clinical characteristics of CHD cases and controls in the Prospect &#x02013;Epic cohort.</title></caption><graphic id="pone-0002533-t001-1" xlink:href="pone.0002533.t001"/><table frame="hsides" rules="groups" alternate-form-of="pone-0002533-t001-1"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td colspan="2" align="left" rowspan="1">Characteristics</td><td colspan="3" align="left" rowspan="1">sub-cohort (N&#x0200a;&#x0003d;&#x0200a;1522)</td><td align="left" rowspan="1" colspan="1"><italic>P</italic>-value<xref ref-type="table-fn" rid="nt103">b</xref></td><td align="left" rowspan="1" colspan="1">CHD cases</td><td align="left" rowspan="1" colspan="1">Sub-cohort</td><td align="left" rowspan="1" colspan="1"><italic>P</italic>-value<xref ref-type="table-fn" rid="nt104">c</xref></td></tr><tr><td colspan="2" align="left" rowspan="1"/><td align="left" rowspan="1" colspan="1">M235M</td><td align="left" rowspan="1" colspan="1">M235T</td><td align="left" rowspan="1" colspan="1">T235T</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td colspan="2" align="left" rowspan="1">N total (&#x00025;)</td><td align="left" rowspan="1" colspan="1">535 (35.2)</td><td align="left" rowspan="1" colspan="1">737 (48.4)</td><td align="left" rowspan="1" colspan="1">250 (16.4)</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">210</td><td align="left" rowspan="1" colspan="1">1522</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td colspan="2" align="left" rowspan="1">Age at intake (yr) <xref ref-type="table-fn" rid="nt102">a</xref></td><td align="left" rowspan="1" colspan="1">57.1&#x000b1;5.8</td><td align="left" rowspan="1" colspan="1">57.1&#x000b1;6.2</td><td align="left" rowspan="1" colspan="1">57.4&#x000b1;6.3</td><td align="left" rowspan="1" colspan="1">0.83</td><td align="left" rowspan="1" colspan="1">60.5&#x000b1;5.9</td><td align="left" rowspan="1" colspan="1">57.1&#x000b1;6.1</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td colspan="2" align="left" rowspan="1">Body mass index (kg/m<sup>2</sup>) <xref ref-type="table-fn" rid="nt102">a</xref></td><td align="left" rowspan="1" colspan="1">26.0&#x000b1;4.1</td><td align="left" rowspan="1" colspan="1">25.6&#x000b1;3.8</td><td align="left" rowspan="1" colspan="1">25.8&#x000b1;4.1</td><td align="left" rowspan="1" colspan="1">0.19</td><td align="left" rowspan="1" colspan="1">26.8&#x000b1;3.9</td><td align="left" rowspan="1" colspan="1">25.8&#x000b1;4.0</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td colspan="2" align="left" rowspan="1">Weight (kg) <xref ref-type="table-fn" rid="nt102">a</xref></td><td align="left" rowspan="1" colspan="1">70&#x000b1;11</td><td align="left" rowspan="1" colspan="1">69&#x000b1;11</td><td align="left" rowspan="1" colspan="1">69&#x000b1;11</td><td align="left" rowspan="1" colspan="1">0.17</td><td align="left" rowspan="1" colspan="1">71&#x000b1;11</td><td align="left" rowspan="1" colspan="1">69&#x000b1;11</td><td align="left" rowspan="1" colspan="1">0.07</td></tr><tr><td colspan="2" align="left" rowspan="1">Height (cm) <xref ref-type="table-fn" rid="nt102">a</xref></td><td align="left" rowspan="1" colspan="1">164.4&#x000b1;5.9</td><td align="left" rowspan="1" colspan="1">164.2&#x000b1;6.0</td><td align="left" rowspan="1" colspan="1">164.0&#x000b1;6.1</td><td align="left" rowspan="1" colspan="1">0.66</td><td align="left" rowspan="1" colspan="1">162.8&#x000b1;6.0</td><td align="left" rowspan="1" colspan="1">164.3&#x000b1;6.0</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td colspan="2" align="left" rowspan="1">Waist to hip ratio <xref ref-type="table-fn" rid="nt102">a</xref></td><td align="left" rowspan="1" colspan="1">0.794&#x000b1;0.057</td><td align="left" rowspan="1" colspan="1">0.786&#x000b1;0.058</td><td align="left" rowspan="1" colspan="1">0.786&#x000b1;0.055</td><td align="left" rowspan="1" colspan="1">0.03</td><td align="left" rowspan="1" colspan="1">0.813&#x000b1;0.060</td><td align="left" rowspan="1" colspan="1">0.789&#x000b1;0.057</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td colspan="2" align="left" rowspan="1">Hypertension (&#x00025;) <xref ref-type="table-fn" rid="nt105">d</xref></td><td align="left" rowspan="1" colspan="1">39.4</td><td align="left" rowspan="1" colspan="1">41.2</td><td align="left" rowspan="1" colspan="1">48.4</td><td align="left" rowspan="1" colspan="1">0.06</td><td align="left" rowspan="1" colspan="1">60.5</td><td align="left" rowspan="1" colspan="1">41.8</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td colspan="2" align="left" rowspan="1">Systolic blood pressure (mm Hg) <xref ref-type="table-fn" rid="nt102">a</xref></td><td align="left" rowspan="1" colspan="1">131&#x000b1;19</td><td align="left" rowspan="1" colspan="1">133&#x000b1;21</td><td align="left" rowspan="1" colspan="1">135&#x000b1;20</td><td align="left" rowspan="1" colspan="1">0.07</td><td align="left" rowspan="1" colspan="1">143&#x000b1;22</td><td align="left" rowspan="1" colspan="1">133&#x000b1;20</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td colspan="2" align="left" rowspan="1">Diastolic blood pressure (mm Hg) <xref ref-type="table-fn" rid="nt102">a</xref></td><td align="left" rowspan="1" colspan="1">79&#x000b1;10</td><td align="left" rowspan="1" colspan="1">79&#x000b1;11</td><td align="left" rowspan="1" colspan="1">80&#x000b1;11</td><td align="left" rowspan="1" colspan="1">0.14</td><td align="left" rowspan="1" colspan="1">82&#x000b1;11</td><td align="left" rowspan="1" colspan="1">79&#x000b1;11</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td colspan="2" align="left" rowspan="1">Presence of diabetes (&#x00025;)</td><td align="left" rowspan="1" colspan="1">2.2</td><td align="left" rowspan="1" colspan="1">2.0</td><td align="left" rowspan="1" colspan="1">2.8</td><td align="left" rowspan="1" colspan="1">0.78</td><td align="left" rowspan="1" colspan="1">5.7</td><td align="left" rowspan="1" colspan="1">2.2</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td colspan="2" align="left" rowspan="1">Presence of hypercholesterolemia (&#x00025;)</td><td align="left" rowspan="1" colspan="1">3.6</td><td align="left" rowspan="1" colspan="1">4.6</td><td align="left" rowspan="1" colspan="1">2.8</td><td align="left" rowspan="1" colspan="1">0.38</td><td align="left" rowspan="1" colspan="1">11.4</td><td align="left" rowspan="1" colspan="1">3.9</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td colspan="2" align="left" rowspan="1">Current alcohol consumption (&#x00025;)</td><td align="left" rowspan="1" colspan="1">88.7</td><td align="left" rowspan="1" colspan="1">87.1</td><td align="left" rowspan="1" colspan="1">89.2</td><td align="left" rowspan="1" colspan="1">0.60</td><td align="left" rowspan="1" colspan="1">80.7</td><td align="left" rowspan="1" colspan="1">88.0</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking status (&#x00025;)</td><td align="left" rowspan="1" colspan="1">Past</td><td align="left" rowspan="1" colspan="1">35.1</td><td align="left" rowspan="1" colspan="1">33.8</td><td align="left" rowspan="1" colspan="1">36.4</td><td align="left" rowspan="1" colspan="1">0.73</td><td align="left" rowspan="1" colspan="1">26.2</td><td align="left" rowspan="1" colspan="1">34.7</td><td align="left" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Current</td><td align="left" rowspan="1" colspan="1">23.2</td><td align="left" rowspan="1" colspan="1">22.4</td><td align="left" rowspan="1" colspan="1">23.6</td><td align="left" rowspan="1" colspan="1">0.90</td><td align="left" rowspan="1" colspan="1">33.8</td><td align="left" rowspan="1" colspan="1">22.9</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td colspan="2" align="left" rowspan="1">Pack- years <xref ref-type="table-fn" rid="nt106">e</xref></td><td align="left" rowspan="1" colspan="1">6.8&#x000b1;9.5</td><td align="left" rowspan="1" colspan="1">6.5&#x000b1;9.5</td><td align="left" rowspan="1" colspan="1">6.7&#x000b1;9.3</td><td align="left" rowspan="1" colspan="1">0.87</td><td align="left" rowspan="1" colspan="1">9.7&#x000b1;11.4</td><td align="left" rowspan="1" colspan="1">6.7&#x000b1;9.5</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td colspan="2" align="left" rowspan="1">Total cholesterol (mmol/L) <xref ref-type="table-fn" rid="nt102">a</xref></td><td align="left" rowspan="1" colspan="1">5.9&#x000b1;1.0</td><td align="left" rowspan="1" colspan="1">5.8&#x000b1;0.9</td><td align="left" rowspan="1" colspan="1">5.9&#x000b1;1.1</td><td align="left" rowspan="1" colspan="1">0.05</td><td align="left" rowspan="1" colspan="1">6.4&#x000b1;1.0</td><td align="left" rowspan="1" colspan="1">5.9&#x000b1;1.0</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td colspan="2" align="left" rowspan="1">HDL cholesterol (mmol/L) <xref ref-type="table-fn" rid="nt102">a</xref></td><td align="left" rowspan="1" colspan="1">1.6&#x000b1;0.4</td><td align="left" rowspan="1" colspan="1">1.6&#x000b1;0.4</td><td align="left" rowspan="1" colspan="1">1.6&#x000b1;0.4</td><td align="left" rowspan="1" colspan="1">0.33</td><td align="left" rowspan="1" colspan="1">1.4&#x000b1;0.3</td><td align="left" rowspan="1" colspan="1">1.6&#x000b1;0.4</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td colspan="2" align="left" rowspan="1">LDL cholesterol (mmol/L) <xref ref-type="table-fn" rid="nt102">a</xref></td><td align="left" rowspan="1" colspan="1">4.0&#x000b1;1.0</td><td align="left" rowspan="1" colspan="1">3.9&#x000b1;0.9</td><td align="left" rowspan="1" colspan="1">3.9&#x000b1;0.9</td><td align="left" rowspan="1" colspan="1">0.25</td><td align="left" rowspan="1" colspan="1">4.4&#x000b1;1.0</td><td align="left" rowspan="1" colspan="1">3.9&#x000b1;0.9</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td colspan="2" align="left" rowspan="1">Serum glucose (mmol/L) <xref ref-type="table-fn" rid="nt102">a</xref></td><td align="left" rowspan="1" colspan="1">4.6&#x000b1;1.5</td><td align="left" rowspan="1" colspan="1">4.5&#x000b1;1.3</td><td align="left" rowspan="1" colspan="1">4.5&#x000b1;1.2</td><td align="left" rowspan="1" colspan="1">0.52</td><td align="left" rowspan="1" colspan="1">5.1&#x000b1;2.5</td><td align="left" rowspan="1" colspan="1">4.5&#x000b1;1.4</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td></tr></tbody></table><table-wrap-foot><fn id="nt101"><label/><p>HDL, high-density lipoprotein; LDL, low-density lipoprotein; CHD, coronary heart disease (ICD 410&#x02013;414).</p></fn><fn id="nt102"><label>a</label><p>Mean&#x000b1;standard deviation.</p></fn><fn id="nt103"><label>b</label><p>Comparison of risk factors across genotypes, using the ANOVA <italic>F</italic> test (continuous variables) and the &#x003c7;<sup>2</sup> statistic (categorical variables).</p></fn><fn id="nt104"><label>c</label><p>Comparison of risk factors across disease status, using the <italic>independent samples t-test</italic> (continuous variables) and the &#x003c7;<sup>2</sup> statistic (categorical variables).</p></fn><fn id="nt105"><label>d</label><p>Defined as a systolic blood pressure &#x02265;140 mm Hg and/or diastolic blood pressure &#x02265;90 mm Hg and/or questionnaire positive.</p></fn><fn id="nt106"><label>e</label><p>The number of packs of cigarettes smoked per day by the number of years the person has smoked.</p></fn></table-wrap-foot></table-wrap><p>Due to the association of the M235T genotypes with some risk factors of CHD, we presented crude models and models adjusted for hypertension, total cholesterol and waist to hip ratio as potential confounding factors. <xref ref-type="table" rid="pone-0002533-t002">Table 2</xref> presents hazard ratios of AMI and CHD under different genetic models. Under the additive model of inheritance, no increased risk for CHD was found (HR&#x0200a;&#x0003d;&#x0200a;1.20; 95&#x00025; CI, 0.86 to 1.68; <italic>P</italic>&#x0200a;&#x0003d;&#x0200a;<italic>0.28</italic>), which did not alter after adjustment (HR&#x0200a;&#x0003d;&#x0200a;1.17; 95&#x00025; CI, 0.83 to 1.64; <italic>P</italic>&#x0200a;&#x0003d;&#x0200a;<italic>0.38</italic>). The same was true for other comparisons (<xref ref-type="table" rid="pone-0002533-t002">Table 2</xref>). Analyses for AMI risk did not show any statistically significant associations (<xref ref-type="table" rid="pone-0002533-t002">Table 2</xref>).</p><table-wrap id="pone-0002533-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002533.t002</object-id><label>Table 2</label><caption><title>Association of the <italic>AGT</italic> M235T polymorphism and AMI and CHD under different genetic models.</title></caption><graphic id="pone-0002533-t002-2" xlink:href="pone.0002533.t002"/><table frame="hsides" rules="groups" alternate-form-of="pone-0002533-t002-2"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Mode of Inheritance</td><td colspan="3" align="left" rowspan="1">Crude: model 1</td><td colspan="3" align="left" rowspan="1">Adjusted: model 2 <xref ref-type="table-fn" rid="nt109">b</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Hazard ratio</td><td align="left" rowspan="1" colspan="1">95&#x00025; CI</td><td align="left" rowspan="1" colspan="1">P-value</td><td align="left" rowspan="1" colspan="1">Hazard ratio</td><td align="left" rowspan="1" colspan="1">95&#x00025; CI</td><td align="left" rowspan="1" colspan="1">P-value</td></tr></thead><tbody><tr><td colspan="7" align="left" rowspan="1"><bold>AMI</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Additive <xref ref-type="table-fn" rid="nt108">a</xref></td><td align="left" rowspan="1" colspan="1">1.20</td><td align="left" rowspan="1" colspan="1">0.86&#x02013;1.68</td><td align="left" rowspan="1" colspan="1">0.28</td><td align="left" rowspan="1" colspan="1">1.17</td><td align="left" rowspan="1" colspan="1">0.83&#x02013;1.64</td><td align="left" rowspan="1" colspan="1">0.38</td></tr><tr><td align="left" rowspan="1" colspan="1">Recessive (TT vs. M-carriers)</td><td align="left" rowspan="1" colspan="1">0.77</td><td align="left" rowspan="1" colspan="1">0.43&#x02013;1.41</td><td align="left" rowspan="1" colspan="1">0.40</td><td align="left" rowspan="1" colspan="1">0.87</td><td align="left" rowspan="1" colspan="1">0.46&#x02013;1.58</td><td align="left" rowspan="1" colspan="1">0.62</td></tr><tr><td align="left" rowspan="1" colspan="1">Dominant (T-carriers vs. MM)</td><td align="left" rowspan="1" colspan="1">0.79</td><td align="left" rowspan="1" colspan="1">0.47&#x02013;1.32</td><td align="left" rowspan="1" colspan="1">0.36</td><td align="left" rowspan="1" colspan="1">0.79</td><td align="left" rowspan="1" colspan="1">0.46&#x02013;1.33</td><td align="left" rowspan="1" colspan="1">0.37</td></tr><tr><td align="left" rowspan="1" colspan="1">MT vs. MM</td><td align="left" rowspan="1" colspan="1">1.09</td><td align="left" rowspan="1" colspan="1">0.84&#x02013;1.41</td><td align="left" rowspan="1" colspan="1">0.53</td><td align="left" rowspan="1" colspan="1">1.11</td><td align="left" rowspan="1" colspan="1">0. 85&#x02013;1.45</td><td align="left" rowspan="1" colspan="1">0.45</td></tr><tr><td align="left" rowspan="1" colspan="1">TT vs. MM</td><td align="left" rowspan="1" colspan="1">1.21</td><td align="left" rowspan="1" colspan="1">0.86&#x02013;1.70</td><td align="left" rowspan="1" colspan="1">0.28</td><td align="left" rowspan="1" colspan="1">1.17</td><td align="left" rowspan="1" colspan="1">0.83&#x02013;1.63</td><td align="left" rowspan="1" colspan="1">0.38</td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>CHD</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Additive <xref ref-type="table-fn" rid="nt108">a</xref></td><td align="left" rowspan="1" colspan="1">1.14</td><td align="left" rowspan="1" colspan="1">0.93&#x02013;1.39</td><td align="left" rowspan="1" colspan="1">0.20</td><td align="left" rowspan="1" colspan="1">1.11</td><td align="left" rowspan="1" colspan="1">0.90&#x02013;1.38</td><td align="left" rowspan="1" colspan="1">0.33</td></tr><tr><td align="left" rowspan="1" colspan="1">Recessive (TT vs. M-carriers)</td><td align="left" rowspan="1" colspan="1">0.87</td><td align="left" rowspan="1" colspan="1">0.60&#x02013;1.26</td><td align="left" rowspan="1" colspan="1">0.45</td><td align="left" rowspan="1" colspan="1">0.98</td><td align="left" rowspan="1" colspan="1">0.66&#x02013;1.47</td><td align="left" rowspan="1" colspan="1">0.93</td></tr><tr><td align="left" rowspan="1" colspan="1">Dominant (T-carriers vs. MM)</td><td align="left" rowspan="1" colspan="1">0.82</td><td align="left" rowspan="1" colspan="1">0.60&#x02013;1.12</td><td align="left" rowspan="1" colspan="1">0.21</td><td align="left" rowspan="1" colspan="1">0.80</td><td align="left" rowspan="1" colspan="1">0.58&#x02013;1.10</td><td align="left" rowspan="1" colspan="1">0.18</td></tr><tr><td align="left" rowspan="1" colspan="1">MT vs. MM</td><td align="left" rowspan="1" colspan="1">1.09</td><td align="left" rowspan="1" colspan="1">0.93&#x02013;1.27</td><td align="left" rowspan="1" colspan="1">0.31</td><td align="left" rowspan="1" colspan="1">1.13</td><td align="left" rowspan="1" colspan="1">0.95&#x02013;1.34</td><td align="left" rowspan="1" colspan="1">0.16</td></tr><tr><td align="left" rowspan="1" colspan="1">TT vs. MM</td><td align="left" rowspan="1" colspan="1">1.14</td><td align="left" rowspan="1" colspan="1">0.93&#x02013;1.40</td><td align="left" rowspan="1" colspan="1">0.20</td><td align="left" rowspan="1" colspan="1">1.11</td><td align="left" rowspan="1" colspan="1">0.90&#x02013;1.37</td><td align="left" rowspan="1" colspan="1">0.33</td></tr></tbody></table><table-wrap-foot><fn id="nt107"><label/><p>AMI&#x0200a;&#x0003d;&#x0200a;acute myocardial infarction (ICD 410); CHD&#x0200a;&#x0003d;&#x0200a;coronary heart disease (ICD 410&#x02013;414).</p></fn><fn id="nt108"><label>a</label><p>The additive genetic model assumes that there is a linear gradient in risk between the MM, MT and TT genotypes (MM genotype baseline). This is equivalent to a comparison of the T allele versus the M allele (baseline).</p></fn><fn id="nt109"><label>b</label><p>We used a cox proportional hazards model with an estimation procedure adapted for case-cohort designs; adjusted for waist to hip ratio, hypertension, total cholesterol.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><title>Meta-Analysis results</title><p><bold><italic>Flow of included studies</italic></bold>. A total of 44 gene-disease association studies, including the present study, evaluating the <italic>AGT</italic> M235T gene variant and CHD risk were identified. Seven articles were excluded, three of which were duplicate publications <xref ref-type="bibr" rid="pone.0002533-Sethi1">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Berdeli1">&#x0005b;23&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-FernandezArcas1">&#x0005b;24&#x0005d;</xref>, three of which did not provide relevant data <xref ref-type="bibr" rid="pone.0002533-Zee1">&#x0005b;25&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0002533-Krizanova1">&#x0005b;27&#x0005d;</xref>, and one of which studied the risk of recurrent coronary events <xref ref-type="bibr" rid="pone.0002533-Goldenberg1">&#x0005b;28&#x0005d;</xref>. Finally, 37 studies met the selection criteria. In one paper, the provided results were based on two different studies <xref ref-type="bibr" rid="pone.0002533-Ludwig1">&#x0005b;6&#x0005d;</xref>, so both were included in the meta-analysis. Therefore, 38 studies with 13,284 cases and 18,722 controls were included in the final meta-analysis (<xref ref-type="fig" rid="pone-0002533-g001">Figure 1</xref>).</p><fig id="pone-0002533-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002533.g001</object-id><label>Figure 1</label><caption><title>Flow chart of study selection.</title></caption><graphic xlink:href="pone.0002533.g001"/></fig></sec><sec id="s3c"><title>Study characteristics</title><p>Characteristics of the studies are shown in <xref ref-type="table" rid="pone-0002533-t003">Table 3</xref><xref ref-type="bibr" rid="pone.0002533-Ludwig1">&#x0005b;6&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0002533-RodriguezPerez1">&#x0005b;8&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Sekuri1">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Nair1">&#x0005b;11&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Tiret1">&#x0005b;13&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Sethi3">&#x0005b;29&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0002533-YamakawaKobayashi1">&#x0005b;58&#x0005d;</xref>. There were 25 studies in Caucasians, eight studies in East Asians, and five studies in other populations (West Asian, South Asian, African, African-American, and South American). The last was collapsed into a miscellaneous group. The design of the studies was case-control, except for three studies that were prospective cohort <xref ref-type="bibr" rid="pone.0002533-Wierzbicki1">&#x0005b;56&#x0005d;</xref>, case-cohort (present study), and cross-sectional <xref ref-type="bibr" rid="pone.0002533-Gardemann1">&#x0005b;40&#x0005d;</xref>. The T allele frequency varied from 26 to 54 percent in Caucasians, 65 to 91 percent in East Asians, and 34 to 83 percent in the miscellaneous group.</p><table-wrap id="pone-0002533-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002533.t003</object-id><label>Table 3</label><caption><title>Characteristics of published studies of the association between the M235T polymorphism in <italic>AGT</italic> gene and CHD included in the meta-analysis.</title></caption><graphic id="pone-0002533-t003-3" xlink:href="pone.0002533.t003"/><table frame="hsides" rules="groups" alternate-form-of="pone-0002533-t003-3"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Author</td><td align="left" rowspan="1" colspan="1">Year</td><td align="left" rowspan="1" colspan="1">Country</td><td align="left" rowspan="1" colspan="1">Ethnicity</td><td align="left" rowspan="1" colspan="1">Total cases</td><td align="left" rowspan="1" colspan="1">Total controls</td><td align="left" rowspan="1" colspan="1">Study size based on average weight</td><td align="left" rowspan="1" colspan="1">Cases MM</td><td align="left" rowspan="1" colspan="1">Cases MT</td><td align="left" rowspan="1" colspan="1">Cases TT</td><td align="left" rowspan="1" colspan="1">Controls MM</td><td align="left" rowspan="1" colspan="1">Controls MT</td><td align="left" rowspan="1" colspan="1">Controls TT</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Katsuya et al. <xref ref-type="bibr" rid="pone.0002533-Katsuya1">&#x0005b;45&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">1995</td><td align="left" rowspan="1" colspan="1">New Zealand</td><td align="left" rowspan="1" colspan="1">Caucasian</td><td align="left" rowspan="1" colspan="1">422</td><td align="left" rowspan="1" colspan="1">406</td><td align="left" rowspan="1" colspan="1">Large</td><td align="left" rowspan="1" colspan="1">144</td><td align="left" rowspan="1" colspan="1">186</td><td align="left" rowspan="1" colspan="1">92</td><td align="left" rowspan="1" colspan="1">156</td><td align="left" rowspan="1" colspan="1">191</td><td align="left" rowspan="1" colspan="1">59</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">Tiret et al. <xref ref-type="bibr" rid="pone.0002533-Tiret1">&#x0005b;13&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">1995</td><td align="left" rowspan="1" colspan="1">France and UK</td><td align="left" rowspan="1" colspan="1">Caucasian</td><td align="left" rowspan="1" colspan="1">630</td><td align="left" rowspan="1" colspan="1">741</td><td align="left" rowspan="1" colspan="1">Large</td><td align="left" rowspan="1" colspan="1">229</td><td align="left" rowspan="1" colspan="1">301</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">258</td><td align="left" rowspan="1" colspan="1">372</td><td align="left" rowspan="1" colspan="1">111</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">Ludwig et al.<sup>a</sup><xref ref-type="bibr" rid="pone.0002533-Ludwig1">&#x0005b;6&#x0005d;</xref> (Framingham study)</td><td align="left" rowspan="1" colspan="1">1997</td><td align="left" rowspan="1" colspan="1">USA</td><td align="left" rowspan="1" colspan="1">Caucasian</td><td align="left" rowspan="1" colspan="1">58</td><td align="left" rowspan="1" colspan="1">55</td><td align="left" rowspan="1" colspan="1">Small</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">23</td><td align="left" rowspan="1" colspan="1">12</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Ludwig et al.<sup>b</sup><xref ref-type="bibr" rid="pone.0002533-Ludwig1">&#x0005b;6&#x0005d;</xref> (ARIC study)</td><td align="left" rowspan="1" colspan="1">1997</td><td align="left" rowspan="1" colspan="1">USA</td><td align="left" rowspan="1" colspan="1">Caucasian</td><td align="left" rowspan="1" colspan="1">255</td><td align="left" rowspan="1" colspan="1">245</td><td align="left" rowspan="1" colspan="1">Large</td><td align="left" rowspan="1" colspan="1">79</td><td align="left" rowspan="1" colspan="1">117</td><td align="left" rowspan="1" colspan="1">59</td><td align="left" rowspan="1" colspan="1">85</td><td align="left" rowspan="1" colspan="1">118</td><td align="left" rowspan="1" colspan="1">42</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">Wenzel et al. <xref ref-type="bibr" rid="pone.0002533-Wenzel1">&#x0005b;55&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">1997</td><td align="left" rowspan="1" colspan="1">Germany</td><td align="left" rowspan="1" colspan="1">Caucasian</td><td align="left" rowspan="1" colspan="1">111</td><td align="left" rowspan="1" colspan="1">102</td><td align="left" rowspan="1" colspan="1">Small</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">59</td><td align="left" rowspan="1" colspan="1">27</td><td align="left" rowspan="1" colspan="1">39</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">17</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">Winkelmann et al. <xref ref-type="bibr" rid="pone.0002533-Winkelmann1">&#x0005b;57&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">1999</td><td align="left" rowspan="1" colspan="1">Germany</td><td align="left" rowspan="1" colspan="1">Caucasian</td><td align="left" rowspan="1" colspan="1">329</td><td align="left" rowspan="1" colspan="1">92</td><td align="left" rowspan="1" colspan="1">Small</td><td align="left" rowspan="1" colspan="1">103</td><td align="left" rowspan="1" colspan="1">148</td><td align="left" rowspan="1" colspan="1">78</td><td align="left" rowspan="1" colspan="1">28</td><td align="left" rowspan="1" colspan="1">53</td><td align="left" rowspan="1" colspan="1">11</td></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">Fernandez-Arcas et al. <xref ref-type="bibr" rid="pone.0002533-FernandezArcas2">&#x0005b;37&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">1999</td><td align="left" rowspan="1" colspan="1">Spain</td><td align="left" rowspan="1" colspan="1">Caucasian</td><td align="left" rowspan="1" colspan="1">272</td><td align="left" rowspan="1" colspan="1">182</td><td align="left" rowspan="1" colspan="1">Small</td><td align="left" rowspan="1" colspan="1">84</td><td align="left" rowspan="1" colspan="1">132</td><td align="left" rowspan="1" colspan="1">56</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">96</td><td align="left" rowspan="1" colspan="1">50</td></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">Gardemann et al. <xref ref-type="bibr" rid="pone.0002533-Gardemann1">&#x0005b;40&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">1999</td><td align="left" rowspan="1" colspan="1">Germany</td><td align="left" rowspan="1" colspan="1">Caucasian</td><td align="left" rowspan="1" colspan="1">1739</td><td align="left" rowspan="1" colspan="1">511</td><td align="left" rowspan="1" colspan="1">Large</td><td align="left" rowspan="1" colspan="1">536</td><td align="left" rowspan="1" colspan="1">920</td><td align="left" rowspan="1" colspan="1">283</td><td align="left" rowspan="1" colspan="1">168</td><td align="left" rowspan="1" colspan="1">247</td><td align="left" rowspan="1" colspan="1">96</td></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">Fatini et al. <xref ref-type="bibr" rid="pone.0002533-Fatini1">&#x0005b;36&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">2000</td><td align="left" rowspan="1" colspan="1">Italy</td><td align="left" rowspan="1" colspan="1">Caucasian</td><td align="left" rowspan="1" colspan="1">205</td><td align="left" rowspan="1" colspan="1">209</td><td align="left" rowspan="1" colspan="1">Small</td><td align="left" rowspan="1" colspan="1">61</td><td align="left" rowspan="1" colspan="1">91</td><td align="left" rowspan="1" colspan="1">53</td><td align="left" rowspan="1" colspan="1">84</td><td align="left" rowspan="1" colspan="1">86</td><td align="left" rowspan="1" colspan="1">39</td></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">Fomicheva et al. <xref ref-type="bibr" rid="pone.0002533-Fomicheva1">&#x0005b;38&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">2000</td><td align="left" rowspan="1" colspan="1">Russia</td><td align="left" rowspan="1" colspan="1">Caucasian</td><td align="left" rowspan="1" colspan="1">198</td><td align="left" rowspan="1" colspan="1">152</td><td align="left" rowspan="1" colspan="1">Small</td><td align="left" rowspan="1" colspan="1">63</td><td align="left" rowspan="1" colspan="1">85</td><td align="left" rowspan="1" colspan="1">50</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1">75</td><td align="left" rowspan="1" colspan="1">34</td></tr><tr><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">Reinhardt et al. <xref ref-type="bibr" rid="pone.0002533-Reinhardt1">&#x0005b;50&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">2000</td><td align="left" rowspan="1" colspan="1">Germany</td><td align="left" rowspan="1" colspan="1">Caucasian</td><td align="left" rowspan="1" colspan="1">184</td><td align="left" rowspan="1" colspan="1">155</td><td align="left" rowspan="1" colspan="1">Small</td><td align="left" rowspan="1" colspan="1">56</td><td align="left" rowspan="1" colspan="1">101</td><td align="left" rowspan="1" colspan="1">27</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">91</td><td align="left" rowspan="1" colspan="1">26</td></tr><tr><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">Batalla et al. <xref ref-type="bibr" rid="pone.0002533-Batalla1">&#x0005b;31&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">2000</td><td align="left" rowspan="1" colspan="1">Spain</td><td align="left" rowspan="1" colspan="1">Caucasian</td><td align="left" rowspan="1" colspan="1">220</td><td align="left" rowspan="1" colspan="1">200</td><td align="left" rowspan="1" colspan="1">Small</td><td align="left" rowspan="1" colspan="1">69</td><td align="left" rowspan="1" colspan="1">99</td><td align="left" rowspan="1" colspan="1">52</td><td align="left" rowspan="1" colspan="1">64</td><td align="left" rowspan="1" colspan="1">96</td><td align="left" rowspan="1" colspan="1">40</td></tr><tr><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">Wierzbicki et al. <xref ref-type="bibr" rid="pone.0002533-Wierzbicki1">&#x0005b;56&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">2000</td><td align="left" rowspan="1" colspan="1">UK</td><td align="left" rowspan="1" colspan="1">Caucasian</td><td align="left" rowspan="1" colspan="1">48</td><td align="left" rowspan="1" colspan="1">108</td><td align="left" rowspan="1" colspan="1">Small</td><td align="left" rowspan="1" colspan="1">23</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">58</td><td align="left" rowspan="1" colspan="1">44</td><td align="left" rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">Rodriguez-Perez et al. <xref ref-type="bibr" rid="pone.0002533-RodriguezPerez1">&#x0005b;8&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">2001</td><td align="left" rowspan="1" colspan="1">Spain</td><td align="left" rowspan="1" colspan="1">Caucasian</td><td align="left" rowspan="1" colspan="1">299</td><td align="left" rowspan="1" colspan="1">315</td><td align="left" rowspan="1" colspan="1">Large</td><td align="left" rowspan="1" colspan="1">67</td><td align="left" rowspan="1" colspan="1">145</td><td align="left" rowspan="1" colspan="1">87</td><td align="left" rowspan="1" colspan="1">97</td><td align="left" rowspan="1" colspan="1">158</td><td align="left" rowspan="1" colspan="1">60</td></tr><tr><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">Olivieri et al. <xref ref-type="bibr" rid="pone.0002533-Olivieri1">&#x0005b;7&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">2001</td><td align="left" rowspan="1" colspan="1">Italy</td><td align="left" rowspan="1" colspan="1">Caucasian</td><td align="left" rowspan="1" colspan="1">454</td><td align="left" rowspan="1" colspan="1">245</td><td align="left" rowspan="1" colspan="1">Large</td><td align="left" rowspan="1" colspan="1">148</td><td align="left" rowspan="1" colspan="1">205</td><td align="left" rowspan="1" colspan="1">101</td><td align="left" rowspan="1" colspan="1">74</td><td align="left" rowspan="1" colspan="1">114</td><td align="left" rowspan="1" colspan="1">57</td></tr><tr><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">Sethi et al. <xref ref-type="bibr" rid="pone.0002533-Sethi3">&#x0005b;29&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">2001</td><td align="left" rowspan="1" colspan="1">Denmark</td><td align="left" rowspan="1" colspan="1">Caucasian</td><td align="left" rowspan="1" colspan="1">943</td><td align="left" rowspan="1" colspan="1">7975</td><td align="left" rowspan="1" colspan="1">Large</td><td align="left" rowspan="1" colspan="1">335</td><td align="left" rowspan="1" colspan="1">460</td><td align="left" rowspan="1" colspan="1">148</td><td align="left" rowspan="1" colspan="1">2779</td><td align="left" rowspan="1" colspan="1">3886</td><td align="left" rowspan="1" colspan="1">1310</td></tr><tr><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">Ortlepp et al. <xref ref-type="bibr" rid="pone.0002533-Ortlepp1">&#x0005b;48&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">2002</td><td align="left" rowspan="1" colspan="1">Germany</td><td align="left" rowspan="1" colspan="1">Caucasian</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">Small</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">58</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">29</td><td align="left" rowspan="1" colspan="1">55</td><td align="left" rowspan="1" colspan="1">16</td></tr><tr><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">Ermis et al. <xref ref-type="bibr" rid="pone.0002533-Ermis1">&#x0005b;35&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">2002</td><td align="left" rowspan="1" colspan="1">Turkey</td><td align="left" rowspan="1" colspan="1">Caucasian</td><td align="left" rowspan="1" colspan="1">102</td><td align="left" rowspan="1" colspan="1">114</td><td align="left" rowspan="1" colspan="1">Small</td><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">48</td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">39</td><td align="left" rowspan="1" colspan="1">59</td><td align="left" rowspan="1" colspan="1">16</td></tr><tr><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">Bis et al. <xref ref-type="bibr" rid="pone.0002533-Bis1">&#x0005b;32&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">2003</td><td align="left" rowspan="1" colspan="1">USA</td><td align="left" rowspan="1" colspan="1">Caucasian</td><td align="left" rowspan="1" colspan="1">208</td><td align="left" rowspan="1" colspan="1">717</td><td align="left" rowspan="1" colspan="1">Large</td><td align="left" rowspan="1" colspan="1">71</td><td align="left" rowspan="1" colspan="1">98</td><td align="left" rowspan="1" colspan="1">39</td><td align="left" rowspan="1" colspan="1">215</td><td align="left" rowspan="1" colspan="1">349</td><td align="left" rowspan="1" colspan="1">153</td></tr><tr><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">Buraczynska et al. <xref ref-type="bibr" rid="pone.0002533-Buraczynska1">&#x0005b;33&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">2003</td><td align="left" rowspan="1" colspan="1">Poland</td><td align="left" rowspan="1" colspan="1">Caucasian</td><td align="left" rowspan="1" colspan="1">200</td><td align="left" rowspan="1" colspan="1">200</td><td align="left" rowspan="1" colspan="1">Small</td><td align="left" rowspan="1" colspan="1">28</td><td align="left" rowspan="1" colspan="1">122</td><td align="left" rowspan="1" colspan="1">50</td><td align="left" rowspan="1" colspan="1">72</td><td align="left" rowspan="1" colspan="1">80</td><td align="left" rowspan="1" colspan="1">48</td></tr><tr><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">Tobin et al. <xref ref-type="bibr" rid="pone.0002533-Tobin1">&#x0005b;53&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">2004</td><td align="left" rowspan="1" colspan="1">UK</td><td align="left" rowspan="1" colspan="1">Caucasian</td><td align="left" rowspan="1" colspan="1">547</td><td align="left" rowspan="1" colspan="1">505</td><td align="left" rowspan="1" colspan="1">Large</td><td align="left" rowspan="1" colspan="1">212</td><td align="left" rowspan="1" colspan="1">252</td><td align="left" rowspan="1" colspan="1">83</td><td align="left" rowspan="1" colspan="1">197</td><td align="left" rowspan="1" colspan="1">226</td><td align="left" rowspan="1" colspan="1">82</td></tr><tr><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">Sekuri et al. <xref ref-type="bibr" rid="pone.0002533-Sekuri1">&#x0005b;10&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">2005</td><td align="left" rowspan="1" colspan="1">Turkey</td><td align="left" rowspan="1" colspan="1">Caucasian</td><td align="left" rowspan="1" colspan="1">115</td><td align="left" rowspan="1" colspan="1">128</td><td align="left" rowspan="1" colspan="1">Small</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">27</td><td align="left" rowspan="1" colspan="1">33</td><td align="left" rowspan="1" colspan="1">71</td><td align="left" rowspan="1" colspan="1">24</td></tr><tr><td align="left" rowspan="1" colspan="1">23</td><td align="left" rowspan="1" colspan="1">Methot et al. <xref ref-type="bibr" rid="pone.0002533-Methot1">&#x0005b;47&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">2005</td><td align="left" rowspan="1" colspan="1">Canada</td><td align="left" rowspan="1" colspan="1">Caucasian</td><td align="left" rowspan="1" colspan="1">198</td><td align="left" rowspan="1" colspan="1">149</td><td align="left" rowspan="1" colspan="1">Small</td><td align="left" rowspan="1" colspan="1">65</td><td align="left" rowspan="1" colspan="1">93</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">60</td><td align="left" rowspan="1" colspan="1">70</td><td align="left" rowspan="1" colspan="1">19</td></tr><tr><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">Renner et al. <xref ref-type="bibr" rid="pone.0002533-Renner1">&#x0005b;51&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">2005</td><td align="left" rowspan="1" colspan="1">Austria</td><td align="left" rowspan="1" colspan="1">Caucasian</td><td align="left" rowspan="1" colspan="1">2582</td><td align="left" rowspan="1" colspan="1">732</td><td align="left" rowspan="1" colspan="1">Large</td><td align="left" rowspan="1" colspan="1">841</td><td align="left" rowspan="1" colspan="1">1205</td><td align="left" rowspan="1" colspan="1">536</td><td align="left" rowspan="1" colspan="1">237</td><td align="left" rowspan="1" colspan="1">357</td><td align="left" rowspan="1" colspan="1">138</td></tr><tr><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">Zafarmand et al. (present study)</td><td align="left" rowspan="1" colspan="1">2008</td><td align="left" rowspan="1" colspan="1">Netherlands</td><td align="left" rowspan="1" colspan="1">Caucasian</td><td align="left" rowspan="1" colspan="1">210</td><td align="left" rowspan="1" colspan="1">1522</td><td align="left" rowspan="1" colspan="1">Large</td><td align="left" rowspan="1" colspan="1">64</td><td align="left" rowspan="1" colspan="1">108</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">535</td><td align="left" rowspan="1" colspan="1">737</td><td align="left" rowspan="1" colspan="1">250</td></tr><tr><td align="left" rowspan="1" colspan="1">26</td><td align="left" rowspan="1" colspan="1">Kamitani et al. <xref ref-type="bibr" rid="pone.0002533-Kamitani1">&#x0005b;44&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">1995</td><td align="left" rowspan="1" colspan="1">Japan</td><td align="left" rowspan="1" colspan="1">East Asian</td><td align="left" rowspan="1" colspan="1">103</td><td align="left" rowspan="1" colspan="1">103</td><td align="left" rowspan="1" colspan="1">Small</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">52</td></tr><tr><td align="left" rowspan="1" colspan="1">27</td><td align="left" rowspan="1" colspan="1">Ishigami et al. <xref ref-type="bibr" rid="pone.0002533-Ishigami1">&#x0005b;43&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">1995</td><td align="left" rowspan="1" colspan="1">Japan</td><td align="left" rowspan="1" colspan="1">East Asian</td><td align="left" rowspan="1" colspan="1">82</td><td align="left" rowspan="1" colspan="1">160</td><td align="left" rowspan="1" colspan="1">Small</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">54</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">51</td><td align="left" rowspan="1" colspan="1">79</td></tr><tr><td align="left" rowspan="1" colspan="1">28</td><td align="left" rowspan="1" colspan="1">Yamakawa-Kobayashi et al. <xref ref-type="bibr" rid="pone.0002533-YamakawaKobayashi1">&#x0005b;58&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">1995</td><td align="left" rowspan="1" colspan="1">Japan</td><td align="left" rowspan="1" colspan="1">East Asian</td><td align="left" rowspan="1" colspan="1">315</td><td align="left" rowspan="1" colspan="1">380</td><td align="left" rowspan="1" colspan="1">Small</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">91</td><td align="left" rowspan="1" colspan="1">209</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">131</td><td align="left" rowspan="1" colspan="1">240</td></tr><tr><td align="left" rowspan="1" colspan="1">29</td><td align="left" rowspan="1" colspan="1">Ko et al. <xref ref-type="bibr" rid="pone.0002533-Ko1">&#x0005b;46&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">1997</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">East Asian</td><td align="left" rowspan="1" colspan="1">267</td><td align="left" rowspan="1" colspan="1">337</td><td align="left" rowspan="1" colspan="1">Small</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">225</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">54</td><td align="left" rowspan="1" colspan="1">279</td></tr><tr><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">Ichihara et al. <xref ref-type="bibr" rid="pone.0002533-Ichihara1">&#x0005b;42&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">1997</td><td align="left" rowspan="1" colspan="1">Japan</td><td align="left" rowspan="1" colspan="1">East Asian</td><td align="left" rowspan="1" colspan="1">327</td><td align="left" rowspan="1" colspan="1">352</td><td align="left" rowspan="1" colspan="1">Small</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">103</td><td align="left" rowspan="1" colspan="1">209</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">112</td><td align="left" rowspan="1" colspan="1">227</td></tr><tr><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">Cong et al. <xref ref-type="bibr" rid="pone.0002533-Cong1">&#x0005b;34&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">1998</td><td align="left" rowspan="1" colspan="1">Japan</td><td align="left" rowspan="1" colspan="1">East Asian</td><td align="left" rowspan="1" colspan="1">104</td><td align="left" rowspan="1" colspan="1">170</td><td align="left" rowspan="1" colspan="1">Small</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">71</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1">111</td></tr><tr><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">Sheu et al. <xref ref-type="bibr" rid="pone.0002533-Sheu1">&#x0005b;52&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">1998</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">East Asian</td><td align="left" rowspan="1" colspan="1">102</td><td align="left" rowspan="1" colspan="1">145</td><td align="left" rowspan="1" colspan="1">Small</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">26</td><td align="left" rowspan="1" colspan="1">75</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">37</td><td align="left" rowspan="1" colspan="1">107</td></tr><tr><td align="left" rowspan="1" colspan="1">33</td><td align="left" rowspan="1" colspan="1">Tsai et al. <xref ref-type="bibr" rid="pone.0002533-Tsai1">&#x0005b;54&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">2006</td><td align="left" rowspan="1" colspan="1">Taiwan</td><td align="left" rowspan="1" colspan="1">East Asian</td><td align="left" rowspan="1" colspan="1">735</td><td align="left" rowspan="1" colspan="1">519</td><td align="left" rowspan="1" colspan="1">Large</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">195</td><td align="left" rowspan="1" colspan="1">525</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">111</td><td align="left" rowspan="1" colspan="1">403</td></tr><tr><td align="left" rowspan="1" colspan="1">34</td><td align="left" rowspan="1" colspan="1">Frossard et al. <xref ref-type="bibr" rid="pone.0002533-Frossard1">&#x0005b;39&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">1998</td><td align="left" rowspan="1" colspan="1">UAE</td><td align="left" rowspan="1" colspan="1">Arab</td><td align="left" rowspan="1" colspan="1">74</td><td align="left" rowspan="1" colspan="1">61</td><td align="left" rowspan="1" colspan="1">Small</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">26</td><td align="left" rowspan="1" colspan="1">19</td></tr><tr><td align="left" rowspan="1" colspan="1">35</td><td align="left" rowspan="1" colspan="1">Hooper et al. <xref ref-type="bibr" rid="pone.0002533-Hooper1">&#x0005b;41&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">2002</td><td align="left" rowspan="1" colspan="1">USA</td><td align="left" rowspan="1" colspan="1">African- American</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">Small</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">29</td><td align="left" rowspan="1" colspan="1">67</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">67</td></tr><tr><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">Nair et al. <xref ref-type="bibr" rid="pone.0002533-Nair1">&#x0005b;11&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">2003</td><td align="left" rowspan="1" colspan="1">India</td><td align="left" rowspan="1" colspan="1">South Asian</td><td align="left" rowspan="1" colspan="1">141</td><td align="left" rowspan="1" colspan="1">131</td><td align="left" rowspan="1" colspan="1">Small</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">96</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">80</td></tr><tr><td align="left" rowspan="1" colspan="1">37</td><td align="left" rowspan="1" colspan="1">Araujo et al. <xref ref-type="bibr" rid="pone.0002533-Araujo1">&#x0005b;30&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">2004</td><td align="left" rowspan="1" colspan="1">Brazil</td><td align="left" rowspan="1" colspan="1">South American</td><td align="left" rowspan="1" colspan="1">110</td><td align="left" rowspan="1" colspan="1">104</td><td align="left" rowspan="1" colspan="1">Small</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">52</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1">51</td><td align="left" rowspan="1" colspan="1">10</td></tr><tr><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">Ranjith et al. <xref ref-type="bibr" rid="pone.0002533-Ranjith1">&#x0005b;49&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">2004</td><td align="left" rowspan="1" colspan="1">South Africa</td><td align="left" rowspan="1" colspan="1">African</td><td align="left" rowspan="1" colspan="1">195</td><td align="left" rowspan="1" colspan="1">300</td><td align="left" rowspan="1" colspan="1">Small</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">80</td><td align="left" rowspan="1" colspan="1">91</td><td align="left" rowspan="1" colspan="1">29</td><td align="left" rowspan="1" colspan="1">127</td><td align="left" rowspan="1" colspan="1">144</td></tr></tbody></table><table frame="hsides" rules="groups" alternate-form-of="pone-0002533-t003-3"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Author</td><td align="left" rowspan="1" colspan="1">Study design</td><td align="left" rowspan="1" colspan="1">Mean age&#x000b1;SD (years) in Cases</td><td align="left" rowspan="1" colspan="1">Mean age&#x000b1;SD (years) in Controls</td><td align="left" rowspan="1" colspan="1">Sex</td><td align="left" rowspan="1" colspan="1">Male percent</td><td align="left" rowspan="1" colspan="1">Matching variable (s)</td><td align="left" rowspan="1" colspan="1">Allele frequency 235T (&#x00025;)</td><td align="left" rowspan="1" colspan="1"><italic>P (HWE)</italic></td><td align="left" rowspan="1" colspan="1">Blinding of genotyping staff</td><td align="left" rowspan="1" colspan="1">Regenotyping of random subsample</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Katsuya et al. <xref ref-type="bibr" rid="pone.0002533-Katsuya1">&#x0005b;45&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">Case-control</td><td align="left" rowspan="1" colspan="1">62&#x000b1;7</td><td align="left" rowspan="1" colspan="1">62&#x000b1;7</td><td align="left" rowspan="1" colspan="1">M/F</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">0.97</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Tiret et al. <xref ref-type="bibr" rid="pone.0002533-Tiret1">&#x0005b;13&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">Case-control</td><td align="left" rowspan="1" colspan="1">54&#x000b1;0.3</td><td align="left" rowspan="1" colspan="1">53&#x000b1;0.3</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">0.22</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Ludwig et al.<sup>a</sup><xref ref-type="bibr" rid="pone.0002533-Ludwig1">&#x0005b;6&#x0005d;</xref> (Framingham study)</td><td align="left" rowspan="1" colspan="1">Case-control</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">M/F</td><td align="left" rowspan="1" colspan="1">86</td><td align="left" rowspan="1" colspan="1">Age and sex</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1">0.28</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Ludwig et al.<sup>b</sup><xref ref-type="bibr" rid="pone.0002533-Ludwig1">&#x0005b;6&#x0005d;</xref> (ARIC study)</td><td align="left" rowspan="1" colspan="1">Case-control</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">M/F</td><td align="left" rowspan="1" colspan="1">80.5</td><td align="left" rowspan="1" colspan="1">Age and sex</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">0.92</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Wenzel et al. <xref ref-type="bibr" rid="pone.0002533-Wenzel1">&#x0005b;55&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">Case-control</td><td align="left" rowspan="1" colspan="1">42<xref ref-type="table-fn" rid="nt111">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">38<xref ref-type="table-fn" rid="nt111">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">M/F</td><td align="left" rowspan="1" colspan="1">88</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">39</td><td align="left" rowspan="1" colspan="1">0.59</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Winkelmann et al. <xref ref-type="bibr" rid="pone.0002533-Winkelmann1">&#x0005b;57&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">Case-control</td><td align="left" rowspan="1" colspan="1">56&#x000b1;10</td><td align="left" rowspan="1" colspan="1">56&#x000b1;10</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">0.06</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Fernandez-Arcas et al. <xref ref-type="bibr" rid="pone.0002533-FernandezArcas2">&#x0005b;37&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">Case-control</td><td align="left" rowspan="1" colspan="1">67&#x000b1;7</td><td align="left" rowspan="1" colspan="1">60&#x000b1;10</td><td align="left" rowspan="1" colspan="1">M/F</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">54</td><td align="left" rowspan="1" colspan="1">0.41</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Gardemann et al. <xref ref-type="bibr" rid="pone.0002533-Gardemann1">&#x0005b;40&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">Cross-sectional</td><td align="left" rowspan="1" colspan="1">63&#x000b1;9</td><td align="left" rowspan="1" colspan="1">59&#x000b1;11</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1">0.76</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Fatini et al. <xref ref-type="bibr" rid="pone.0002533-Fatini1">&#x0005b;36&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">Case-control</td><td align="left" rowspan="1" colspan="1">59&#x000b1;5</td><td align="left" rowspan="1" colspan="1">51&#x000b1;6</td><td align="left" rowspan="1" colspan="1">M/F</td><td align="left" rowspan="1" colspan="1">76</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">39</td><td align="left" rowspan="1" colspan="1">0.0476</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Fomicheva et al. <xref ref-type="bibr" rid="pone.0002533-Fomicheva1">&#x0005b;38&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">Case-control</td><td align="left" rowspan="1" colspan="1">67</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">47</td><td align="left" rowspan="1" colspan="1">0.90</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Reinhardt et al. <xref ref-type="bibr" rid="pone.0002533-Reinhardt1">&#x0005b;50&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">Case-control</td><td align="left" rowspan="1" colspan="1">57&#x000b1;11</td><td align="left" rowspan="1" colspan="1">56&#x000b1;14</td><td align="left" rowspan="1" colspan="1">M/F</td><td align="left" rowspan="1" colspan="1">62</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">0.0240</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Batalla et al. <xref ref-type="bibr" rid="pone.0002533-Batalla1">&#x0005b;31&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">Case-control</td><td align="left" rowspan="1" colspan="1">43&#x000b1;5</td><td align="left" rowspan="1" colspan="1">42&#x000b1;6</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">Age and ethnicity</td><td align="left" rowspan="1" colspan="1">44</td><td align="left" rowspan="1" colspan="1">0.71</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Wierzbicki et al. <xref ref-type="bibr" rid="pone.0002533-Wierzbicki1">&#x0005b;56&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">Cohort</td><td align="left" rowspan="1" colspan="1">57&#x000b1;13</td><td align="left" rowspan="1" colspan="1">53&#x000b1;12</td><td align="left" rowspan="1" colspan="1">M/F</td><td align="left" rowspan="1" colspan="1">68</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">26</td><td align="left" rowspan="1" colspan="1">0.53</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Rodriguez-Perez et al. <xref ref-type="bibr" rid="pone.0002533-RodriguezPerez1">&#x0005b;8&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">Case-control</td><td align="left" rowspan="1" colspan="1">56&#x000b1;10</td><td align="left" rowspan="1" colspan="1">54&#x000b1;10</td><td align="left" rowspan="1" colspan="1">M/F</td><td align="left" rowspan="1" colspan="1">76</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">44</td><td align="left" rowspan="1" colspan="1">0.76</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Olivieri et al. <xref ref-type="bibr" rid="pone.0002533-Olivieri1">&#x0005b;7&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">Case-control</td><td align="left" rowspan="1" colspan="1">60&#x000b1;9</td><td align="left" rowspan="1" colspan="1">58&#x000b1;13</td><td align="left" rowspan="1" colspan="1">M/F</td><td align="left" rowspan="1" colspan="1">83.5</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">47</td><td align="left" rowspan="1" colspan="1">0.31</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Sethi et al. <xref ref-type="bibr" rid="pone.0002533-Sethi3">&#x0005b;29&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">Case-control</td><td align="left" rowspan="1" colspan="1">59&#x000b1;9</td><td align="left" rowspan="1" colspan="1">56&#x000b1;15</td><td align="left" rowspan="1" colspan="1">M/F</td><td align="left" rowspan="1" colspan="1">74</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">0.43</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Ortlepp et al. <xref ref-type="bibr" rid="pone.0002533-Ortlepp1">&#x0005b;48&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">Case-control</td><td align="left" rowspan="1" colspan="1">58&#x000b1;13</td><td align="left" rowspan="1" colspan="1">59&#x000b1;11</td><td align="left" rowspan="1" colspan="1">M/F</td><td align="left" rowspan="1" colspan="1">68</td><td align="left" rowspan="1" colspan="1">Age, sex, and prevalence of standard cardiac risk factors</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1">0.23</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Ermis et al. <xref ref-type="bibr" rid="pone.0002533-Ermis1">&#x0005b;35&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">Case-control</td><td align="left" rowspan="1" colspan="1">42&#x000b1;12</td><td align="left" rowspan="1" colspan="1">40&#x000b1;13</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">0.40</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Bis et al. <xref ref-type="bibr" rid="pone.0002533-Bis1">&#x0005b;32&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">Case-control</td><td align="left" rowspan="1" colspan="1">70</td><td align="left" rowspan="1" colspan="1">64</td><td align="left" rowspan="1" colspan="1">M/F</td><td align="left" rowspan="1" colspan="1">61.5</td><td align="left" rowspan="1" colspan="1">Age, sex and calendar year of identification</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">0.61</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Buraczynska et al. <xref ref-type="bibr" rid="pone.0002533-Buraczynska1">&#x0005b;33&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">Case-control</td><td align="left" rowspan="1" colspan="1">53&#x000b1;7</td><td align="left" rowspan="1" colspan="1">47&#x000b1;11</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">44</td><td align="left" rowspan="1" colspan="1">0.0077</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Tobin et al. <xref ref-type="bibr" rid="pone.0002533-Tobin1">&#x0005b;53&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">Case-control</td><td align="left" rowspan="1" colspan="1">62&#x000b1;9</td><td align="left" rowspan="1" colspan="1">57&#x000b1;11</td><td align="left" rowspan="1" colspan="1">M/F</td><td align="left" rowspan="1" colspan="1">68</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">39</td><td align="left" rowspan="1" colspan="1">0.21</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Sekuri et al. <xref ref-type="bibr" rid="pone.0002533-Sekuri1">&#x0005b;10&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">Case-control</td><td align="left" rowspan="1" colspan="1">48&#x000b1;8</td><td align="left" rowspan="1" colspan="1">44&#x000b1;7</td><td align="left" rowspan="1" colspan="1">M/F</td><td align="left" rowspan="1" colspan="1">77.4</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">47</td><td align="left" rowspan="1" colspan="1">0.19</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Methot et al. <xref ref-type="bibr" rid="pone.0002533-Methot1">&#x0005b;47&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">Case-control</td><td align="left" rowspan="1" colspan="1">63&#x000b1;10</td><td align="left" rowspan="1" colspan="1">62&#x000b1;7</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">37</td><td align="left" rowspan="1" colspan="1">0.84</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Renner et al. <xref ref-type="bibr" rid="pone.0002533-Renner1">&#x0005b;51&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">Case-control</td><td align="left" rowspan="1" colspan="1">64&#x000b1;10</td><td align="left" rowspan="1" colspan="1">58&#x000b1;12</td><td align="left" rowspan="1" colspan="1">M/F</td><td align="left" rowspan="1" colspan="1">74.8</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1">0.86</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Zafarmand et al. (present study)</td><td align="left" rowspan="1" colspan="1">Case-cohort</td><td align="left" rowspan="1" colspan="1">61&#x000b1;6</td><td align="left" rowspan="1" colspan="1">57&#x000b1;6</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">0.89</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Kamitani et al. <xref ref-type="bibr" rid="pone.0002533-Kamitani1">&#x0005b;44&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">Case-control</td><td align="left" rowspan="1" colspan="1">52&#x000b1;1</td><td align="left" rowspan="1" colspan="1">54&#x000b1;1</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">Age, sex, BMI, blood pressure, total cholesterol, smoking and history of diabetes</td><td align="left" rowspan="1" colspan="1">70</td><td align="left" rowspan="1" colspan="1">0.65</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Ishigami et al. <xref ref-type="bibr" rid="pone.0002533-Ishigami1">&#x0005b;43&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">Case-control</td><td align="left" rowspan="1" colspan="1">62&#x000b1;1</td><td align="left" rowspan="1" colspan="1">60&#x000b1;1</td><td align="left" rowspan="1" colspan="1">M/F</td><td align="left" rowspan="1" colspan="1">68.3</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">65</td><td align="left" rowspan="1" colspan="1">0.0002</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Yamakawa-Kobayashi et al. <xref ref-type="bibr" rid="pone.0002533-YamakawaKobayashi1">&#x0005b;58&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">Case-control</td><td align="left" rowspan="1" colspan="1">57&#x000b1;8</td><td align="left" rowspan="1" colspan="1">51&#x000b1;8</td><td align="left" rowspan="1" colspan="1">M/F</td><td align="left" rowspan="1" colspan="1">80</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">80</td><td align="left" rowspan="1" colspan="1">0.07</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Ko et al. <xref ref-type="bibr" rid="pone.0002533-Ko1">&#x0005b;46&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">Case-control</td><td align="left" rowspan="1" colspan="1">62&#x000b1;1</td><td align="left" rowspan="1" colspan="1">56&#x000b1;1</td><td align="left" rowspan="1" colspan="1">M/F</td><td align="left" rowspan="1" colspan="1">77</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">91</td><td align="left" rowspan="1" colspan="1">0.51<xref ref-type="table-fn" rid="nt111">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Ichihara et al. <xref ref-type="bibr" rid="pone.0002533-Ichihara1">&#x0005b;42&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">Case-control</td><td align="left" rowspan="1" colspan="1">53&#x000b1;6</td><td align="left" rowspan="1" colspan="1">53&#x000b1;5</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">Age, sex, BMI and some CHD risk factors (history of smoking, hypertension, diabetes, hypercholesterolemia)</td><td align="left" rowspan="1" colspan="1">80</td><td align="left" rowspan="1" colspan="1">0.86</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Cong et al. <xref ref-type="bibr" rid="pone.0002533-Cong1">&#x0005b;34&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">Case-control</td><td align="left" rowspan="1" colspan="1">65&#x000b1;1</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">M/F</td><td align="left" rowspan="1" colspan="1">76</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">78</td><td align="left" rowspan="1" colspan="1">0.0006</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Sheu et al. <xref ref-type="bibr" rid="pone.0002533-Sheu1">&#x0005b;52&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">Case-control</td><td align="left" rowspan="1" colspan="1">63&#x000b1;1</td><td align="left" rowspan="1" colspan="1">58&#x000b1;1</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">87</td><td align="left" rowspan="1" colspan="1">0.47<xref ref-type="table-fn" rid="nt111">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Tsai et al. <xref ref-type="bibr" rid="pone.0002533-Tsai1">&#x0005b;54&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">Case-control</td><td align="left" rowspan="1" colspan="1">64&#x000b1;11</td><td align="left" rowspan="1" colspan="1">59&#x000b1;13</td><td align="left" rowspan="1" colspan="1">M/F</td><td align="left" rowspan="1" colspan="1">72.2</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">88</td><td align="left" rowspan="1" colspan="1">0.38</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Frossard et al. <xref ref-type="bibr" rid="pone.0002533-Frossard1">&#x0005b;39&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">Case-control</td><td align="left" rowspan="1" colspan="1">57&#x000b1;12</td><td align="left" rowspan="1" colspan="1">54&#x000b1;14</td><td align="left" rowspan="1" colspan="1">M/F</td><td align="left" rowspan="1" colspan="1">48.2</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">52</td><td align="left" rowspan="1" colspan="1">0.26</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Hooper et al. <xref ref-type="bibr" rid="pone.0002533-Hooper1">&#x0005b;41&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">Case-control</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">M/F</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">83</td><td align="left" rowspan="1" colspan="1">0.73<xref ref-type="table-fn" rid="nt111">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Nair et al. <xref ref-type="bibr" rid="pone.0002533-Nair1">&#x0005b;11&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">Case-control</td><td align="left" rowspan="1" colspan="1">56&#x000b1;5</td><td align="left" rowspan="1" colspan="1">48&#x000b1;6</td><td align="left" rowspan="1" colspan="1">M/F</td><td align="left" rowspan="1" colspan="1">82.3</td><td align="left" rowspan="1" colspan="1">Age and sex</td><td align="left" rowspan="1" colspan="1">76</td><td align="left" rowspan="1" colspan="1">0.08</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Araujo et al. <xref ref-type="bibr" rid="pone.0002533-Araujo1">&#x0005b;30&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">Case-control</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">M/F</td><td align="left" rowspan="1" colspan="1">66.6</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">34</td><td align="left" rowspan="1" colspan="1">0.36</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Ranjith et al. <xref ref-type="bibr" rid="pone.0002533-Ranjith1">&#x0005b;49&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">Case-control</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">M/F</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">69</td><td align="left" rowspan="1" colspan="1">0.90</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td></tr></tbody></table><table frame="hsides" rules="groups" alternate-form-of="pone-0002533-t003-3"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Author</td><td align="left" rowspan="1" colspan="1">End point</td><td align="left" rowspan="1" colspan="1">Case definition</td><td align="left" rowspan="1" colspan="1">Source of controls</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Katsuya et al. <xref ref-type="bibr" rid="pone.0002533-Katsuya1">&#x0005b;45&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">CHD</td><td align="left" rowspan="1" colspan="1">Admission for treatment of myocardial infarction or unstable angina, PTCA, or CABG, or stable angina with angiographic evidence of CHD or a positive exercise test result</td><td align="left" rowspan="1" colspan="1">Controls without a history of CHD and symptoms suggesting angina from two previous studies</td></tr><tr><td align="left" rowspan="1" colspan="1">Tiret et al. <xref ref-type="bibr" rid="pone.0002533-Tiret1">&#x0005b;13&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">MI</td><td align="left" rowspan="1" colspan="1">WHO MONICA category I</td><td align="left" rowspan="1" colspan="1">Electoral rolls in France and the list of general practitioners in N. Ireland</td></tr><tr><td align="left" rowspan="1" colspan="1">Ludwig et al.<sup>a</sup><xref ref-type="bibr" rid="pone.0002533-Ludwig1">&#x0005b;6&#x0005d;</xref> (Framingham study)</td><td align="left" rowspan="1" colspan="1">CHD</td><td align="left" rowspan="1" colspan="1">Diagnosed MI by a physician, a PTCA, a CABG, prior MI in ECG, fatal CHD</td><td align="left" rowspan="1" colspan="1">Healthy controls without the conditions, no lipid-lowering medications and no family history</td></tr><tr><td align="left" rowspan="1" colspan="1">Ludwig et al.<sup>b</sup><xref ref-type="bibr" rid="pone.0002533-Ludwig1">&#x0005b;6&#x0005d;</xref> (ARIC study)</td><td align="left" rowspan="1" colspan="1">CHD</td><td align="left" rowspan="1" colspan="1">Diagnosed MI by a physician, a percutaneous coronary angioplasty, a coronary artery bypass, prior MI, fatal CHD</td><td align="left" rowspan="1" colspan="1">Healthy controls without the conditions, no lipid-lowering medications and no family history</td></tr><tr><td align="left" rowspan="1" colspan="1">Wenzel et al. <xref ref-type="bibr" rid="pone.0002533-Wenzel1">&#x0005b;55&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">CHD</td><td align="left" rowspan="1" colspan="1">&#x0003e;50&#x00025; stenosis of at least one major coronary vessel, defined as MI, PTCA, CABG</td><td align="left" rowspan="1" colspan="1">Healthy young persons without any symptoms for CVD</td></tr><tr><td align="left" rowspan="1" colspan="1">Winkelmann et al. <xref ref-type="bibr" rid="pone.0002533-Winkelmann1">&#x0005b;57&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">CHD, MI</td><td align="left" rowspan="1" colspan="1">At least one coronary stenosis &#x02265; 50&#x00025;</td><td align="left" rowspan="1" colspan="1">controls without coronary artery disease in coronary angiography</td></tr><tr><td align="left" rowspan="1" colspan="1">Fernandez-Arcas et al. <xref ref-type="bibr" rid="pone.0002533-FernandezArcas2">&#x0005b;37&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">MI</td><td align="left" rowspan="1" colspan="1">Typical prolonged chest pain or atypical symptoms, acute congestive heart failure, syncope, and serial cardiac enzymes elevation exceeding twice the upper limit of reference range and dynamic ECG changes typical of MI</td><td align="left" rowspan="1" colspan="1">Healthy controls with no CVD using health service identity card</td></tr><tr><td align="left" rowspan="1" colspan="1">Gardemann et al. <xref ref-type="bibr" rid="pone.0002533-Gardemann1">&#x0005b;40&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">CHD, MI</td><td align="left" rowspan="1" colspan="1">CHD: coronary stenosis &#x02265; 50&#x00025; MI: Using the WHO criteria</td><td align="left" rowspan="1" colspan="1">No vessel disease in the coronary angiography</td></tr><tr><td align="left" rowspan="1" colspan="1">Fatini et al. <xref ref-type="bibr" rid="pone.0002533-Fatini1">&#x0005b;36&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">CHD</td><td align="left" rowspan="1" colspan="1">History of CHD (previous MI or angina pectoris) with coronary stenosis &#x0003e;75&#x00025; by angiography</td><td align="left" rowspan="1" colspan="1">Random healthy controls from the staff of the University</td></tr><tr><td align="left" rowspan="1" colspan="1">Fomicheva et al. <xref ref-type="bibr" rid="pone.0002533-Fomicheva1">&#x0005b;38&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">MI</td><td align="left" rowspan="1" colspan="1">Using the WHO criteria</td><td align="left" rowspan="1" colspan="1">From secondary schools</td></tr><tr><td align="left" rowspan="1" colspan="1">Reinhardt et al. <xref ref-type="bibr" rid="pone.0002533-Reinhardt1">&#x0005b;50&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">CHD</td><td align="left" rowspan="1" colspan="1">At least one coronary stenosis &#x02265; 50&#x00025; of a major coronary artery with or without prior MI</td><td align="left" rowspan="1" colspan="1">Random healthy controls from the local registry office</td></tr><tr><td align="left" rowspan="1" colspan="1">Batalla et al. <xref ref-type="bibr" rid="pone.0002533-Batalla1">&#x0005b;31&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">MI</td><td align="left" rowspan="1" colspan="1">WHO MONICA protocol</td><td align="left" rowspan="1" colspan="1">Healthy controls from residents of the region</td></tr><tr><td align="left" rowspan="1" colspan="1">Wierzbicki et al. <xref ref-type="bibr" rid="pone.0002533-Wierzbicki1">&#x0005b;56&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">CHD</td><td align="left" rowspan="1" colspan="1">Confirmed cardiac event, angioplasty, coronary bypass surgery, or significant lesions on angiography</td><td align="left" rowspan="1" colspan="1">No CHD</td></tr><tr><td align="left" rowspan="1" colspan="1">Rodriguez-Perez et al. <xref ref-type="bibr" rid="pone.0002533-RodriguezPerez1">&#x0005b;8&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">CHD</td><td align="left" rowspan="1" colspan="1">Hospital-admitted with a diagnosis of MI or unstable angina and documented evidence of coronary artery disease by angiography</td><td align="left" rowspan="1" colspan="1">Random controls without CVD</td></tr><tr><td align="left" rowspan="1" colspan="1">Olivieri et al. <xref ref-type="bibr" rid="pone.0002533-Olivieri1">&#x0005b;7&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">CHD, MI</td><td align="left" rowspan="1" colspan="1">CHD: Candidate patients for CABG, having &#x0003e;50&#x00025; stenosis of at least one major coronary vessel MI: By medical records showing diagnostic electrocardiogram and enzyme changes, and/or the typical sequelae of myocardial infarction on ventricular angiography</td><td align="left" rowspan="1" colspan="1">CHD-free group documented by angiography who were examined for other reasons in the institute</td></tr><tr><td align="left" rowspan="1" colspan="1">Sethi et al. <xref ref-type="bibr" rid="pone.0002533-Sethi3">&#x0005b;29&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">CHD, MI</td><td align="left" rowspan="1" colspan="1">CHD: ICD, 8th edition, codes 410-414 MI: ICD, 8th edition, code 410</td><td align="left" rowspan="1" colspan="1">Random healthy controls without CHD, MI or CVA from the city of Copenhagen</td></tr><tr><td align="left" rowspan="1" colspan="1">Ortlepp et al. <xref ref-type="bibr" rid="pone.0002533-Ortlepp1">&#x0005b;48&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">CHD</td><td align="left" rowspan="1" colspan="1">&#x0003e;50&#x00025; stenosis of at least one coronary vessel</td><td align="left" rowspan="1" colspan="1">Patients without any signs of atherosclerosis in angiography</td></tr><tr><td align="left" rowspan="1" colspan="1">Ermis et al. <xref ref-type="bibr" rid="pone.0002533-Ermis1">&#x0005b;35&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">Early MI</td><td align="left" rowspan="1" colspan="1">WHO criteria</td><td align="left" rowspan="1" colspan="1">Healthy subjects without a history of CHD, hypertension or diabetes</td></tr><tr><td align="left" rowspan="1" colspan="1">Bis et al. <xref ref-type="bibr" rid="pone.0002533-Bis1">&#x0005b;32&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">MI</td><td align="left" rowspan="1" colspan="1">Criteria were adapted from the Cardiovascular Health Study</td><td align="left" rowspan="1" colspan="1">Randomly selected subjects from the members of a health maintenance organization</td></tr><tr><td align="left" rowspan="1" colspan="1">Buraczynska et al. <xref ref-type="bibr" rid="pone.0002533-Buraczynska1">&#x0005b;33&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">CHD</td><td align="left" rowspan="1" colspan="1">Hospitalized patients with unstable angina, stable angina or acute MI</td><td align="left" rowspan="1" colspan="1">Healthy subjects without family history of CHD</td></tr><tr><td align="left" rowspan="1" colspan="1">Tobin et al. <xref ref-type="bibr" rid="pone.0002533-Tobin1">&#x0005b;53&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">MI</td><td align="left" rowspan="1" colspan="1">Using the WHO criteria</td><td align="left" rowspan="1" colspan="1">Healthy visitors to patients</td></tr><tr><td align="left" rowspan="1" colspan="1">Sekuri et al. <xref ref-type="bibr" rid="pone.0002533-Sekuri1">&#x0005b;10&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">CHD</td><td align="left" rowspan="1" colspan="1">At least one stenosis &#x02265; 50&#x00025; in a major coronary artery or one of their branches</td><td align="left" rowspan="1" colspan="1">Healthy subjects without history of CVD</td></tr><tr><td align="left" rowspan="1" colspan="1">Methot et al. <xref ref-type="bibr" rid="pone.0002533-Methot1">&#x0005b;47&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">CHD</td><td align="left" rowspan="1" colspan="1">Acute coronary syndrome: AMI or unstable angina defined according to standard criteria</td><td align="left" rowspan="1" colspan="1">Postmenopausal women without signs or symptoms of acute or previous acute coronary syndrome</td></tr><tr><td align="left" rowspan="1" colspan="1">Renner et al. <xref ref-type="bibr" rid="pone.0002533-Renner1">&#x0005b;51&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">CHD, MI</td><td align="left" rowspan="1" colspan="1">CHD: At least one stenosis &#x02265; 50&#x00025; in one of 15 coronary segments MI: positive history of MI or patients presented with ST elevation or non-ST elevation</td><td align="left" rowspan="1" colspan="1">Subjects without CHD (with stenoses &#x0003c;20&#x00025;) from a cohort study</td></tr><tr><td align="left" rowspan="1" colspan="1">Zafarmand et al. (present study)</td><td align="left" rowspan="1" colspan="1">CHD, MI</td><td align="left" rowspan="1" colspan="1">CHD: ICD, 9th edition, codes 410-414 MI: ICD, 9th edition, code 410</td><td align="left" rowspan="1" colspan="1">Members of a 10&#x00025; random sample from the whole cohort at the baseline without CVD</td></tr><tr><td align="left" rowspan="1" colspan="1">Kamitani et al. <xref ref-type="bibr" rid="pone.0002533-Kamitani1">&#x0005b;44&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">MI</td><td align="left" rowspan="1" colspan="1">Having MI by coronary angiography, ECG criteria, and measurements of heart-specific serum enzymes</td><td align="left" rowspan="1" colspan="1">Randomly selected subjects attending the same hospital with no CVD</td></tr><tr><td align="left" rowspan="1" colspan="1">Ishigami et al. <xref ref-type="bibr" rid="pone.0002533-Ishigami1">&#x0005b;43&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">CHD</td><td align="left" rowspan="1" colspan="1">At least one coronary artery with &#x0003e;25&#x00025; luminal obstruction on average according to multiple coronary angiographic views</td><td align="left" rowspan="1" colspan="1">Hospital-admitted patients for other diseases with no CHD</td></tr><tr><td align="left" rowspan="1" colspan="1">Yamakawa-Kobayashi et al. <xref ref-type="bibr" rid="pone.0002533-YamakawaKobayashi1">&#x0005b;58&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">CHD</td><td align="left" rowspan="1" colspan="1">At least one 75&#x00025; stenosis in coronary arteries</td><td align="left" rowspan="1" colspan="1">Healthy controls</td></tr><tr><td align="left" rowspan="1" colspan="1">Ko et al. <xref ref-type="bibr" rid="pone.0002533-Ko1">&#x0005b;46&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">CHD</td><td align="left" rowspan="1" colspan="1">&#x0003e;50&#x00025; stenosis of at least one major coronary vessel</td><td align="left" rowspan="1" colspan="1">Healthy subjects and patients without angiographic evidence of CHD</td></tr><tr><td align="left" rowspan="1" colspan="1">Ichihara et al. <xref ref-type="bibr" rid="pone.0002533-Ichihara1">&#x0005b;42&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">CHD</td><td align="left" rowspan="1" colspan="1">MI was based on typical ECG changes and increased serum enzymes and by the presence of wall motion abnormality on left ventriculography, Angina pectoris by typical ECG changes and stenosis of &#x0003e;70&#x00025; in any major coronary artery or of &#x0003e;50&#x00025; in the left main trunk, without wall motion abnormality on left ventriculography</td><td align="left" rowspan="1" colspan="1">Random healthy controls with no history or sign of CHD from attendants of the hospitals</td></tr><tr><td align="left" rowspan="1" colspan="1">Cong et al. <xref ref-type="bibr" rid="pone.0002533-Cong1">&#x0005b;34&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">CHD</td><td align="left" rowspan="1" colspan="1">&#x02265; 50&#x00025; stenosis in at least one major coronary artery</td><td align="left" rowspan="1" colspan="1">Subjects with no history of CHD or abnormal resting electrocardiogram</td></tr><tr><td align="left" rowspan="1" colspan="1">Sheu et al. <xref ref-type="bibr" rid="pone.0002533-Sheu1">&#x0005b;52&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">CHD</td><td align="left" rowspan="1" colspan="1">A postnitroglycerin stenosis of major vessels &#x02265; 50&#x00025; or a &#x0003e;70&#x00025; reduction of luminal diameter of a first-order branche</td><td align="left" rowspan="1" colspan="1">Healthy subjects in their annual physical checkups</td></tr><tr><td align="left" rowspan="1" colspan="1">Tsai et al. <xref ref-type="bibr" rid="pone.0002533-Tsai1">&#x0005b;54&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">CHD</td><td align="left" rowspan="1" colspan="1">&#x0003e;50&#x00025; stenosis of at least one coronary vessel</td><td align="left" rowspan="1" colspan="1">CHD-free group documented by angiography</td></tr><tr><td align="left" rowspan="1" colspan="1">Frossard et al. <xref ref-type="bibr" rid="pone.0002533-Frossard1">&#x0005b;39&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">CHD, MI</td><td align="left" rowspan="1" colspan="1">CHD: Exertional angina, unstable angina or MI MI: ECG changes; presence of regional wall motion abnormalities on trans-thoracic echocardiography; and serial enzyme elevations</td><td align="left" rowspan="1" colspan="1">Healthy controls</td></tr><tr><td align="left" rowspan="1" colspan="1">Hooper et al. <xref ref-type="bibr" rid="pone.0002533-Hooper1">&#x0005b;41&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">MI</td><td align="left" rowspan="1" colspan="1">Prior MI confirmed by ECG and/or cardiac enzymes or cardiac thallium scanning or catheterization</td><td align="left" rowspan="1" colspan="1">Outpatients with no history of heart attack, stroke, or thrombosis</td></tr><tr><td align="left" rowspan="1" colspan="1">Nair et al. <xref ref-type="bibr" rid="pone.0002533-Nair1">&#x0005b;11&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">CHD</td><td align="left" rowspan="1" colspan="1">At least one coronary artery with 50&#x00025; stenosis</td><td align="left" rowspan="1" colspan="1">Healthy controls with BP&#x0003c;140/90 mm Hg and no history of CVD</td></tr><tr><td align="left" rowspan="1" colspan="1">Araujo et al. <xref ref-type="bibr" rid="pone.0002533-Araujo1">&#x0005b;30&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">MI</td><td align="left" rowspan="1" colspan="1">Using the WHO criteria confirmed by stenosis &#x0003e;50&#x00025; in an angiography and ventricular damage in a ventriculography</td><td align="left" rowspan="1" colspan="1">Hospital-admitted patients for other diseases with a normal coronary angiography</td></tr><tr><td align="left" rowspan="1" colspan="1">Ranjith et al. <xref ref-type="bibr" rid="pone.0002533-Ranjith1">&#x0005b;49&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">MI</td><td align="left" rowspan="1" colspan="1">Using the WHO criteria</td><td align="left" rowspan="1" colspan="1">Healthy normotensive subjects with no CVD or other associated risk factors</td></tr></tbody></table><table-wrap-foot><fn id="nt110"><label/><p>PTCA, percutaneous coronary angioplasty; CABG, coronary artery bypass graft; ICD, international classification of diseases; ECG, electrocardiography; AMI, acute myocardial infarction; CHD, coronary heart disease; CVD, cardiovascular diseases; CVA, cerebrovascular accident; BMI, body mass index; WHO, world health organization; NR, not reported.</p></fn><fn id="nt111"><label>&#x0002a;</label><p>Exact significance probability.</p></fn></table-wrap-foot></table-wrap><p>All studies used polymerase chain reaction methods for genotyping, and most used a restriction fragment length method for polymorphism analysis. Blinding of investigators involved in genotyping with respect to the case/control status of the participants was reported in six studies <xref ref-type="bibr" rid="pone.0002533-RodriguezPerez1">&#x0005b;8&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Bis1">&#x0005b;32&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Reinhardt1">&#x0005b;50&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Renner1">&#x0005b;51&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Wierzbicki1">&#x0005b;56&#x0005d;</xref>. A random double-check to detect potential genotyping errors was mentioned in five studies <xref ref-type="bibr" rid="pone.0002533-FernandezArcas2">&#x0005b;37&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Reinhardt1">&#x0005b;50&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Tobin1">&#x0005b;53&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Wierzbicki1">&#x0005b;56&#x0005d;</xref>. In most of the studies, the genotype frequencies were consistent with HWE. However, statistically significant deviations from HWE were found in five studies (<xref ref-type="table" rid="pone-0002533-t003">Table 3</xref>) <xref ref-type="bibr" rid="pone.0002533-Buraczynska1">&#x0005b;33&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Cong1">&#x0005b;34&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Fatini1">&#x0005b;36&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Ishigami1">&#x0005b;43&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Reinhardt1">&#x0005b;50&#x0005d;</xref>. CHD cases were defined in 16 studies as a &#x0003e;50&#x00025; stenosis of at least one coronary vessel <xref ref-type="bibr" rid="pone.0002533-Olivieri1">&#x0005b;7&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-RodriguezPerez1">&#x0005b;8&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Sekuri1">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Nair1">&#x0005b;11&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Cong1">&#x0005b;34&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Gardemann1">&#x0005b;40&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Hooper1">&#x0005b;41&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Ishigami1">&#x0005b;43&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Ko1">&#x0005b;46&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Ortlepp1">&#x0005b;48&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Reinhardt1">&#x0005b;50&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Renner1">&#x0005b;51&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Tsai1">&#x0005b;54&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0002533-Winkelmann1">&#x0005b;57&#x0005d;</xref>, while, in four studies, a &#x0003e;70&#x00025; stenosis was considered <xref ref-type="bibr" rid="pone.0002533-Fatini1">&#x0005b;36&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Ichihara1">&#x0005b;42&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Sheu1">&#x0005b;52&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-YamakawaKobayashi1">&#x0005b;58&#x0005d;</xref>. In 14 studies <xref ref-type="bibr" rid="pone.0002533-Tiret1">&#x0005b;13&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Sethi3">&#x0005b;29&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0002533-Bis1">&#x0005b;32&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Ermis1">&#x0005b;35&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-FernandezArcas2">&#x0005b;37&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0002533-Frossard1">&#x0005b;39&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Kamitani1">&#x0005b;44&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Methot1">&#x0005b;47&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Ranjith1">&#x0005b;49&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Tobin1">&#x0005b;53&#x0005d;</xref>, the WHO criteria were used, and, in four studies, CHD was diagnosed based on a clinical diagnosis <xref ref-type="bibr" rid="pone.0002533-Ludwig1">&#x0005b;6&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Buraczynska1">&#x0005b;33&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Katsuya1">&#x0005b;45&#x0005d;</xref>. Controls arose from the source population of the cases in 21 studies <xref ref-type="bibr" rid="pone.0002533-Ludwig1">&#x0005b;6&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-RodriguezPerez1">&#x0005b;8&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Tiret1">&#x0005b;13&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Sethi3">&#x0005b;29&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Batalla1">&#x0005b;31&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0002533-Buraczynska1">&#x0005b;33&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Ermis1">&#x0005b;35&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0002533-Fomicheva1">&#x0005b;38&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Katsuya1">&#x0005b;45&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Methot1">&#x0005b;47&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Ranjith1">&#x0005b;49&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0002533-Tobin1">&#x0005b;53&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Wenzel1">&#x0005b;55&#x0005d;</xref>, while hospital-based/not population-based controls were used in 17 studies <xref ref-type="bibr" rid="pone.0002533-Olivieri1">&#x0005b;7&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Sekuri1">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Nair1">&#x0005b;11&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Araujo1">&#x0005b;30&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Cong1">&#x0005b;34&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Frossard1">&#x0005b;39&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0002533-Kamitani1">&#x0005b;44&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Ko1">&#x0005b;46&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Ortlepp1">&#x0005b;48&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Tsai1">&#x0005b;54&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Wierzbicki1">&#x0005b;56&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0002533-YamakawaKobayashi1">&#x0005b;58&#x0005d;</xref>.</p></sec><sec id="s3d"><title>Quantitative data synthesis</title><p>The overall OR under a random-effects model using an additive model for CHD risk was 1.08 (95&#x00025; CI, 1.01 to 1.15; <italic>P</italic>&#x0200a;&#x0003d;&#x0200a;0.025; <xref ref-type="fig" rid="pone-0002533-g002">Figure 2</xref>). However, there was evidence of substantial between-study heterogeneity (<bold><italic>I<sup>2</sup></italic></bold>&#x0200a;&#x0003d;&#x0200a;55.5&#x00025;, <italic>P</italic>&#x0003c;0.001). <xref ref-type="table" rid="pone-0002533-t004">Table 4</xref> shows the association of the <italic>AGT</italic> T235M polymorphism with CHD risk under different genetic contrasts. When a recessive model was evaluated, a significant association was found between individuals homozygous for the T allele (T235T genotype) and CHD risk, when compared to carriers of the M allele (OR&#x0200a;&#x0003d;&#x0200a;1.11; 95&#x00025; CI, 1.02 to 1.22; <italic>P</italic>&#x0200a;&#x0003d;&#x0200a;0.016). Under the dominant model, the association was not significant. Under pairwise comparisons, there was a significant modest association between the T235T genotype and CHD risk, as compared with the M235M genotype (OR&#x0200a;&#x0003d;&#x0200a;1.15; 95&#x00025; CI, 1.00 to 1.32; <italic>P</italic>&#x0200a;&#x0003d;&#x0200a;0.045). There was evidence for moderate to large between-study heterogeneity under all models (<xref ref-type="table" rid="pone-0002533-t004">Table 4</xref>). Sub-group analysis, by study characteristics under the additive model, showed that matching, blinding of genotyping staff, and regenotyping of a random sub-sample explained little of the heterogeneity. However, stratification showed an attenuated effect estimates in the large studies, in studies that CHD was defined based on angiography or WHO criteria, and in particular in studies that were in HWE (<xref ref-type="table" rid="pone-0002533-t005">Table 5</xref>). Further evaluation of potential sources of the heterogeneity was performed using a meta-regression analysis.</p><fig id="pone-0002533-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002533.g002</object-id><label>Figure 2</label><caption><title>Results of published studies of association between the M235T polymorphism in <italic>AGT</italic> gene and coronary heart disease in different ethnic groups.</title><p>ORs for the outcome compared the T235 allele vs. the M235 allele (Additive model). The size of the box is proportional to the weight of the study. Given <italic>P</italic>-values for odds ratios are based on DerSimonian-Laird method using a random effects model and for heterogeneity in different ethnic groups are based on Q-test.</p></caption><graphic xlink:href="pone.0002533.g002"/></fig><table-wrap id="pone-0002533-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002533.t004</object-id><label>Table 4</label><caption><title>ORs and 95&#x00025; CI for coronary heart disease and the M235T polymorphism in <italic>AGT</italic> gene under different genetic models.</title></caption><graphic id="pone-0002533-t004-4" xlink:href="pone.0002533.t004"/><table frame="hsides" rules="groups" alternate-form-of="pone-0002533-t004-4"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Genetic model</td><td align="left" rowspan="1" colspan="1">Random effects OR (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1"><italic>P</italic>-value</td><td align="left" rowspan="1" colspan="1"><italic>I<sup>2</sup></italic> (&#x00025;) (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1"><bold><italic>Q</italic></bold> statistic for heterogeneity (df&#x0200a;&#x0003d;&#x0200a;37)</td><td align="left" rowspan="1" colspan="1"><italic>P</italic>-value for heterogeneity</td><td align="left" rowspan="1" colspan="1">Egger's test <italic>P</italic>-value</td><td align="left" rowspan="1" colspan="1">Begg's test <italic>P</italic>-value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Additive <xref ref-type="table-fn" rid="nt112">a</xref></td><td align="left" rowspan="1" colspan="1">1.08 (1.01&#x02013;1.15)</td><td align="left" rowspan="1" colspan="1">0.025</td><td align="left" rowspan="1" colspan="1">55.5 (36&#x02013;69)</td><td align="left" rowspan="1" colspan="1">83.21</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">0.066</td><td align="left" rowspan="1" colspan="1">0.074</td></tr><tr><td align="left" rowspan="1" colspan="1">Recessive (TT vs. M-carriers)</td><td align="left" rowspan="1" colspan="1">1.11 (1.02&#x02013;1.22)</td><td align="left" rowspan="1" colspan="1">0.016</td><td align="left" rowspan="1" colspan="1">37.5 (7&#x02013;58)</td><td align="left" rowspan="1" colspan="1">59.23</td><td align="left" rowspan="1" colspan="1">0.012</td><td align="left" rowspan="1" colspan="1">0.011</td><td align="left" rowspan="1" colspan="1">0.070</td></tr><tr><td align="left" rowspan="1" colspan="1">Dominant (T-carriers vs. MM)</td><td align="left" rowspan="1" colspan="1">1.07 (0.96&#x02013;1.19)</td><td align="left" rowspan="1" colspan="1">0.253</td><td align="left" rowspan="1" colspan="1">56.0 (37&#x02013;69)</td><td align="left" rowspan="1" colspan="1">84.02</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">0.549</td><td align="left" rowspan="1" colspan="1">0.706</td></tr><tr><td align="left" rowspan="1" colspan="1">MT vs. MM</td><td align="left" rowspan="1" colspan="1">1.02 (0.91&#x02013;1.14)</td><td align="left" rowspan="1" colspan="1">0.724</td><td align="left" rowspan="1" colspan="1">51.3 (29&#x02013;66)</td><td align="left" rowspan="1" colspan="1">75.99</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">0.895</td><td align="left" rowspan="1" colspan="1">0.960</td></tr><tr><td align="left" rowspan="1" colspan="1">TT vs. MM</td><td align="left" rowspan="1" colspan="1">1.15 (1.00&#x02013;1.32)</td><td align="left" rowspan="1" colspan="1">0.045</td><td align="left" rowspan="1" colspan="1">53.3(33&#x02013;68)</td><td align="left" rowspan="1" colspan="1">79.30</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">0.286</td><td align="left" rowspan="1" colspan="1">0.615</td></tr></tbody></table><table-wrap-foot><fn id="nt112"><label>a</label><p>The additive genetic model assumes that there is a linear gradient in risk between the MM, MT and TT genotypes (MM genotype baseline). This is equivalent to a comparison of the T allele versus the M allele (baseline).</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0002533-t005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002533.t005</object-id><label>Table 5</label><caption><title>Studies of the M235T polymorphism in <italic>AGT</italic> gene and risk of coronary heart disease under additive model grouped by study characteristics.</title></caption><graphic id="pone-0002533-t005-5" xlink:href="pone.0002533.t005"/><table frame="hsides" rules="groups" alternate-form-of="pone-0002533-t005-5"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Study characteristics</td><td align="left" rowspan="1" colspan="1">Number of studies</td><td align="left" rowspan="1" colspan="1">Per-allele OR (95&#x00025;CI)</td><td align="left" rowspan="1" colspan="1"><italic>P</italic>-value</td><td align="left" rowspan="1" colspan="1"><bold><italic>I<sup>2</sup></italic></bold> (&#x00025;) (95&#x00025;CI)</td><td align="left" rowspan="1" colspan="1"><bold><italic>Q</italic></bold> statistic for heterogeneity</td><td align="left" rowspan="1" colspan="1"><italic>P</italic>-value for heterogeneity</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Overall</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">1.08 (1.01&#x02013;1.15)</td><td align="left" rowspan="1" colspan="1">0.025</td><td align="left" rowspan="1" colspan="1">55.5 (36&#x02013;69)</td><td align="left" rowspan="1" colspan="1">83.21</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td colspan="7" align="left" rowspan="1">Study size</td></tr><tr><td align="left" rowspan="1" colspan="1">Small</td><td align="left" rowspan="1" colspan="1">26</td><td align="left" rowspan="1" colspan="1">1.12 (1.02&#x02013;1.24)</td><td align="left" rowspan="1" colspan="1">0.021</td><td align="left" rowspan="1" colspan="1">50.2 (35&#x02013;73)</td><td align="left" rowspan="1" colspan="1">50.24</td><td align="left" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">Large</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">1.03 (0.95&#x02013;1.12)</td><td align="left" rowspan="1" colspan="1">0.502</td><td align="left" rowspan="1" colspan="1">62.0 (29&#x02013;80)</td><td align="left" rowspan="1" colspan="1">28.92</td><td align="left" rowspan="1" colspan="1">0.002</td></tr><tr><td colspan="7" align="left" rowspan="1">Ethnicity</td></tr><tr><td align="left" rowspan="1" colspan="1">Caucasians</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">1.08 (1.01&#x02013;1.17)</td><td align="left" rowspan="1" colspan="1">0.028</td><td align="left" rowspan="1" colspan="1">58.2 (35&#x02013;73)</td><td align="left" rowspan="1" colspan="1">57.43</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Eastern Asians</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">1.12 (0.89&#x02013;1.40)</td><td align="left" rowspan="1" colspan="1">0.325</td><td align="left" rowspan="1" colspan="1">69.5 (36&#x02013;85)</td><td align="left" rowspan="1" colspan="1">22.96</td><td align="left" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">Others</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">0.99 (0.84&#x02013;1.18)</td><td align="left" rowspan="1" colspan="1">0.944</td><td align="left" rowspan="1" colspan="1">0.00 (0&#x02013;79)</td><td align="left" rowspan="1" colspan="1">2.31</td><td align="left" rowspan="1" colspan="1">0.679</td></tr><tr><td colspan="7" align="left" rowspan="1">Matching</td></tr><tr><td align="left" rowspan="1" colspan="1">Matched</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">1.07 (0.96&#x02013;1.18)</td><td align="left" rowspan="1" colspan="1">0.211</td><td align="left" rowspan="1" colspan="1">26.2 (0&#x02013;63)</td><td align="left" rowspan="1" colspan="1">13.56</td><td align="left" rowspan="1" colspan="1">0.194</td></tr><tr><td align="left" rowspan="1" colspan="1">Unmatched</td><td align="left" rowspan="1" colspan="1">27</td><td align="left" rowspan="1" colspan="1">1.08 (0.99&#x02013;1.17)</td><td align="left" rowspan="1" colspan="1">0.072</td><td align="left" rowspan="1" colspan="1">62.7 (44&#x02013;75)</td><td align="left" rowspan="1" colspan="1">69.65</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td colspan="7" align="left" rowspan="1">Violating HWE</td></tr><tr><td align="left" rowspan="1" colspan="1">Violated</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">1.38 (1.05,&#x02013;1.83)</td><td align="left" rowspan="1" colspan="1">0.022</td><td align="left" rowspan="1" colspan="1">70.7 (26&#x02013;88)</td><td align="left" rowspan="1" colspan="1">13.65</td><td align="left" rowspan="1" colspan="1">0.009</td></tr><tr><td align="left" rowspan="1" colspan="1">Confirmed</td><td align="left" rowspan="1" colspan="1">33</td><td align="left" rowspan="1" colspan="1">1.04 (0.98&#x02013;1.11)</td><td align="left" rowspan="1" colspan="1">0.188</td><td align="left" rowspan="1" colspan="1">43.5 (5&#x02013;63)</td><td align="left" rowspan="1" colspan="1">56.66</td><td align="left" rowspan="1" colspan="1">0.005</td></tr><tr><td colspan="7" align="left" rowspan="1">Blinding of genotyping staff</td></tr><tr><td align="left" rowspan="1" colspan="1">Blinded</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">1.07 (0.92&#x02013;1.24)</td><td align="left" rowspan="1" colspan="1">0.391</td><td align="left" rowspan="1" colspan="1">62.6 (9&#x02013;85)</td><td align="left" rowspan="1" colspan="1">13.36</td><td align="left" rowspan="1" colspan="1">0.020</td></tr><tr><td align="left" rowspan="1" colspan="1">Not reported</td><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">1.08 (1.00&#x02013;1.16)</td><td align="left" rowspan="1" colspan="1">0.040</td><td align="left" rowspan="1" colspan="1">55.5 (34&#x02013;70)</td><td align="left" rowspan="1" colspan="1">69.88</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td colspan="7" align="left" rowspan="1">Regenotyping of a random subsample</td></tr><tr><td align="left" rowspan="1" colspan="1">Performed</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">0.94 (0.79&#x02013;1.14)</td><td align="left" rowspan="1" colspan="1">0.544</td><td align="left" rowspan="1" colspan="1">58.9 (0&#x02013;85)</td><td align="left" rowspan="1" colspan="1">9.74</td><td align="left" rowspan="1" colspan="1">0.045</td></tr><tr><td align="left" rowspan="1" colspan="1">Not reported</td><td align="left" rowspan="1" colspan="1">33</td><td align="left" rowspan="1" colspan="1">1.10 (1.03&#x02013;1.18)</td><td align="left" rowspan="1" colspan="1">0.007</td><td align="left" rowspan="1" colspan="1">54.7 (33&#x02013;69)</td><td align="left" rowspan="1" colspan="1">70.64</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td colspan="7" align="left" rowspan="1">Case definition</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;50&#x00025;stenosis of &#x02265;1 major vessels</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">1.09 (0.97&#x02013;1.23)</td><td align="left" rowspan="1" colspan="1">0.135</td><td align="left" rowspan="1" colspan="1">62.4 (35&#x02013;78)</td><td align="left" rowspan="1" colspan="1">39.9</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;70&#x00025;stenosis of &#x02265;1 major vessels</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">1.10 (0.90&#x02013;1.34)</td><td align="left" rowspan="1" colspan="1">0.358</td><td align="left" rowspan="1" colspan="1">40.7 (0&#x02013;80)</td><td align="left" rowspan="1" colspan="1">5.1</td><td align="left" rowspan="1" colspan="1">0.167</td></tr><tr><td align="left" rowspan="1" colspan="1">WHO criteria</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">1.00 (0.93&#x02013;1.09)</td><td align="left" rowspan="1" colspan="1">0.942</td><td align="left" rowspan="1" colspan="1">36.9 (0&#x02013;67)</td><td align="left" rowspan="1" colspan="1">20.6</td><td align="left" rowspan="1" colspan="1">0.081</td></tr><tr><td align="left" rowspan="1" colspan="1">Clinical diagnosis</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">1.31 (1.15&#x02013;1.49)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">0.00 (0&#x02013;85)</td><td align="left" rowspan="1" colspan="1">2.7</td><td align="left" rowspan="1" colspan="1">0.439</td></tr><tr><td colspan="7" align="left" rowspan="1">Source of controls</td></tr><tr><td align="left" rowspan="1" colspan="1">Population-based</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">1.09 (1.01&#x02013;1.19)</td><td align="left" rowspan="1" colspan="1">0.036</td><td align="left" rowspan="1" colspan="1">62.6 (40&#x02013;77)</td><td align="left" rowspan="1" colspan="1">53.5</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Hospital-based</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">1.05 (0.95&#x02013;1.17)</td><td align="left" rowspan="1" colspan="1">0.354</td><td align="left" rowspan="1" colspan="1">44.6 (2&#x02013;69)</td><td align="left" rowspan="1" colspan="1">28.9</td><td align="left" rowspan="1" colspan="1">0.025</td></tr></tbody></table></table-wrap></sec><sec id="s3e"><title>Meta-regression</title><p>First, an empty regression was run with only the log of the effect estimate of pooled studies under the additive model to determine the baseline value for &#x003c4;<sup>2</sup>, an estimate of between-study variation (baseline &#x003c4;<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;0.025). Next, single covariates were added in a series of univariate models. We performed the regression analysis for ten pre-defined potential sources of heterogeneity, including ethnicity, sex, mean age of cases, study size, case definition, source of controls, HWE-violation, blinding in genotyping, performing a sub-sample regenotyping, and matching (we hypothesized that studies that used matching might produce more conservative estimates of association). Univariate regression analyses showed that violation of HWE (&#x003b2; coefficient&#x0200a;&#x0003d;&#x0200a;0.27 (0.06 to 0.48); <italic>P<sub>Het</sub></italic>&#x0200a;&#x0003d;&#x0200a;0.015, &#x003c4;<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;0.019), the mean age of cases (&#x003b2;&#x0200a;&#x0003d;&#x0200a;&#x02212;0.01 (&#x02212;0.02 to 0.0008); <italic>P<sub>Het</sub></italic>&#x0200a;&#x0003d;&#x0200a;0.066, &#x003c4;<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;0.024), and the method of case definition, clinically diagnosed CHD versus WHO criteria adjusted for other definitions (&#x003b2;&#x0200a;&#x0003d;&#x0200a;0.26 (0.02 to 0.50); <italic>P<sub>Het</sub></italic>&#x0200a;&#x0003d;&#x0200a;0.038, &#x003c4;<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;0.020), were significant sources of heterogeneity among studies. The study size (<italic>P<sub>Het</sub></italic>&#x0200a;&#x0003d;&#x0200a;0.241, &#x003c4;<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;0.024), the ethnicity (<italic>P<sub>Het</sub></italic>&#x0200a;&#x0003d;&#x0200a;0.591, &#x003c4;<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;0.025), the male percentage in the study (<italic>P<sub>Het</sub></italic>&#x0200a;&#x0003d;&#x0200a;0.701, &#x003c4;<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;0.029), blinded genotyping (<italic>P<sub>Het</sub></italic>&#x0200a;&#x0003d;&#x0200a;0.890, &#x003c4;<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;0.026), sub-sample regenotyping (<italic>P<sub>Het</sub></italic>&#x0200a;&#x0003d;&#x0200a;0.131, &#x003c4;<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;0.023), the source of controls (<italic>P<sub>Het</sub></italic>&#x0200a;&#x0003d;&#x0200a;0.640, &#x003c4;<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;0.025), and matching (<italic>P<sub>Het</sub></italic>&#x0200a;&#x0003d;&#x0200a;0.942, &#x003c4;<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;0.026) were not significant sources of heterogeneity among studies. Violation of HWE in multivariable regression analysis remained a statistically significant source of heterogeneity after adjustment for the effect of study size (<italic>P<sub>Het</sub></italic>&#x0200a;&#x0003d;&#x0200a;0.031, &#x003c4;<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;0.020). Adding the mean age of cases and method of case definition to the model with violation of HWE decreased the &#x003c4;<sup>2</sup> value to 0.017 (<italic>P<sub>Het</sub></italic>&#x0200a;&#x0003d;&#x0200a;0.073 for violation of HWE, <italic>P<sub>Het</sub></italic>&#x0200a;&#x0003d;&#x0200a;0.057 for the mean age of cases, and <italic>P<sub>Het</sub></italic>&#x0200a;&#x0003d;&#x0200a;0.162 for clinically diagnosed CHD). It also showed that the effect of method of case definition on the variation among the studies was through the effect of the mean age on the heterogeneity and not as an independent factor. A model that included only violation of HWE and the mean age of cases reduced the &#x003c4;<sup>2</sup> value to 0.018 (<italic>P<sub>Het</sub></italic>&#x0200a;&#x0003d;&#x0200a;0.019, and 0.052, respectively).</p></sec><sec id="s3f"><title>Sensitivity Analysis</title><p>First, the influence of deviation from the HWE on effect estimates was examined by using HWE-deviated adjusted ORs. <xref ref-type="table" rid="pone-0002533-t006">Table 6</xref> presents the genotype-based contrasts with corrected ORs, as well as the allele-based contrast. After adjustment, a smaller overall effect was seen under the additive, dominant, and pairwise comparisons. Moreover, after adjustment, the previously significant association under the additive model, as well as the TT vs. MM comparison, was no longer statistically significant. The association under the recessive model still remained significant.</p><table-wrap id="pone-0002533-t006" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002533.t006</object-id><label>Table 6</label><caption><title>ORs and 95&#x00025; CI after adjustment for HWE-deviation under different genetic models.</title></caption><graphic id="pone-0002533-t006-6" xlink:href="pone.0002533.t006"/><table frame="hsides" rules="groups" alternate-form-of="pone-0002533-t006-6"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Genotype contrasts</td><td align="left" rowspan="1" colspan="1">Population</td><td align="left" rowspan="1" colspan="1">Number of studies</td><td colspan="3" align="left" rowspan="1">Random effects model</td><td align="left" rowspan="1" colspan="1"><italic>I<sup>2</sup></italic> (&#x00025;) (95&#x00025;CI)</td><td align="left" rowspan="1" colspan="1"><italic>Q</italic> statistic for heterogeneity</td><td align="left" rowspan="1" colspan="1"><italic>P</italic>-value for heterogeneity</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Odds ratio</td><td align="left" rowspan="1" colspan="1">95&#x00025;CI</td><td align="left" rowspan="1" colspan="1">P-value</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Additive</td><td align="left" rowspan="1" colspan="1">All</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">1.11</td><td align="left" rowspan="1" colspan="1">0.81&#x02013;1.53</td><td align="left" rowspan="1" colspan="1">0.522</td><td align="left" rowspan="1" colspan="1">0 (0&#x02013;37)</td><td align="left" rowspan="1" colspan="1">2.04</td><td align="left" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Caucasians</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">1.11</td><td align="left" rowspan="1" colspan="1">0.75&#x02013;1.64</td><td align="left" rowspan="1" colspan="1">0.616</td><td align="left" rowspan="1" colspan="1">0 (0&#x02013;44)</td><td align="left" rowspan="1" colspan="1">1.04</td><td align="left" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">East Asians</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">1.19</td><td align="left" rowspan="1" colspan="1">0.60&#x02013;2.36</td><td align="left" rowspan="1" colspan="1">0.626</td><td align="left" rowspan="1" colspan="1">0 (0&#x02013;68)</td><td align="left" rowspan="1" colspan="1">0.82</td><td align="left" rowspan="1" colspan="1">0.997</td></tr><tr><td align="left" rowspan="1" colspan="1">Recessive</td><td align="left" rowspan="1" colspan="1">All</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">1.14</td><td align="left" rowspan="1" colspan="1">1.04&#x02013;1.26</td><td align="left" rowspan="1" colspan="1">0.007</td><td align="left" rowspan="1" colspan="1">56 (37&#x02013;70)</td><td align="left" rowspan="1" colspan="1">84.66</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Caucasians</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">1.15</td><td align="left" rowspan="1" colspan="1">1.03&#x02013;1.29</td><td align="left" rowspan="1" colspan="1">0.014</td><td align="left" rowspan="1" colspan="1">56 (32&#x02013;72)</td><td align="left" rowspan="1" colspan="1">55.02</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">East Asians</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">1.18</td><td align="left" rowspan="1" colspan="1">0.90&#x02013;1.55</td><td align="left" rowspan="1" colspan="1">0.242</td><td align="left" rowspan="1" colspan="1">73 (45&#x02013;87)</td><td align="left" rowspan="1" colspan="1">26.15</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Dominant</td><td align="left" rowspan="1" colspan="1">All</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">1.05</td><td align="left" rowspan="1" colspan="1">0.96&#x02013;1.15</td><td align="left" rowspan="1" colspan="1">0.330</td><td align="left" rowspan="1" colspan="1">49 (26&#x02013;65)</td><td align="left" rowspan="1" colspan="1">72.52</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Caucasians</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">1.08</td><td align="left" rowspan="1" colspan="1">0.98&#x02013;1.20</td><td align="left" rowspan="1" colspan="1">0.121</td><td align="left" rowspan="1" colspan="1">58 (35&#x02013;73)</td><td align="left" rowspan="1" colspan="1">57.82</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">East Asians</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">0.92</td><td align="left" rowspan="1" colspan="1">0.64&#x02013;1.33</td><td align="left" rowspan="1" colspan="1">0.656</td><td align="left" rowspan="1" colspan="1">33 (0&#x02013;70)</td><td align="left" rowspan="1" colspan="1">10.41</td><td align="left" rowspan="1" colspan="1">0.166</td></tr><tr><td align="left" rowspan="1" colspan="1">MT vs MM</td><td align="left" rowspan="1" colspan="1">All</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.92&#x02013;1.09</td><td align="left" rowspan="1" colspan="1">0.996</td><td align="left" rowspan="1" colspan="1">15 (0&#x02013;43)</td><td align="left" rowspan="1" colspan="1">43.41</td><td align="left" rowspan="1" colspan="1">0.217</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Caucasians</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">1.03</td><td align="left" rowspan="1" colspan="1">0.94&#x02013;1.14</td><td align="left" rowspan="1" colspan="1">0.497</td><td align="left" rowspan="1" colspan="1">25 (0&#x02013;54)</td><td align="left" rowspan="1" colspan="1">31.99</td><td align="left" rowspan="1" colspan="1">0.127</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">East Asians</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">0.82</td><td align="left" rowspan="1" colspan="1">0.60&#x02013;1.11</td><td align="left" rowspan="1" colspan="1">0.204</td><td align="left" rowspan="1" colspan="1">0 (0&#x02013;68)</td><td align="left" rowspan="1" colspan="1">6.53</td><td align="left" rowspan="1" colspan="1">0.480</td></tr><tr><td align="left" rowspan="1" colspan="1">TT vs MM</td><td align="left" rowspan="1" colspan="1">All</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">1.13</td><td align="left" rowspan="1" colspan="1">0.99&#x02013;1.28</td><td align="left" rowspan="1" colspan="1">0.080</td><td align="left" rowspan="1" colspan="1">52 (31&#x02013;67)</td><td align="left" rowspan="1" colspan="1">77.88</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Caucasians</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">1.19</td><td align="left" rowspan="1" colspan="1">1.02&#x02013;1.38</td><td align="left" rowspan="1" colspan="1">0.023</td><td align="left" rowspan="1" colspan="1">60 (38&#x02013;74)</td><td align="left" rowspan="1" colspan="1">60.11</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">East Asians</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">1.01</td><td align="left" rowspan="1" colspan="1">0.65&#x02013;1.59</td><td align="left" rowspan="1" colspan="1">0.952</td><td align="left" rowspan="1" colspan="1">50 (0&#x02013;77)</td><td align="left" rowspan="1" colspan="1">13.87</td><td align="left" rowspan="1" colspan="1">0.054</td></tr></tbody></table></table-wrap><p><xref ref-type="fig" rid="pone-0002533-g003">Figure 3</xref> shows a funnel plot in which the log of the OR of CHD risk under the additive genetic model was plotted against the standard error of the log of the OR in each study. The funnel plot for the overall results was substantially asymmetric for small negative studies. Moreover, tests for potential publication bias (The Egger's test and the Begg-Mazumdar test; <italic>P</italic>-values equal to 0.066 and 0.074, respectively) suggested the presence of a publication bias. By using the trim and fill method, we showed that, if the publication bias was the only source of the funnel plot asymmetry, it needed seven more studies to be symmetrical (<xref ref-type="fig" rid="pone-0002533-g004">Figure 4</xref>).</p><fig id="pone-0002533-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002533.g003</object-id><label>Figure 3</label><caption><title>Begg's funnel plot with pseudo 95&#x00025; confidence limits under the additive genetic model.</title><p>The size of the circle is proportional to the weight of the study.</p></caption><graphic xlink:href="pone.0002533.g003"/></fig><fig id="pone-0002533-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002533.g004</object-id><label>Figure 4</label><caption><title>Filled Begg's funnel plot with pseudo 95&#x00025; confidence limits under the additive genetic model.</title><p>Red squares are missed studies due to publication bias.</p></caption><graphic xlink:href="pone.0002533.g004"/></fig></sec></sec><sec id="s4"><title>Discussion</title><sec id="s4a"><title>Prospect-EPIC study</title><p>In this prospective study of healthy women aged 49 to 70 years, we investigated the relationship between the M235T polymorphism in the <italic>AGT</italic> gene and risk of AMI and CHD later in life. Under the additive genetic model, increased risks, albeit not statistically significant, were found for the incidence of AMI and CHD, which did not alter after adjustment. Likewise, we did not find a clear association between the variant and risk of CHD or AMI using different genetic models. This may be explained by: (i) the absence of a biological effect, (ii) the presence of real genetic heterogeneity according to ethnic background, or (iii) failure to detect a small effect because the epidemiologic risk for an individual genetic variant is likely to be small and a large sample size is needed for adequate statistical power. It has been commonly proposed that, as well as a need for much larger and more rigorous studies those that are currently used, there is a greater need for international collaborations, particularly for a complex disease like CHD <xref ref-type="bibr" rid="pone.0002533-Seminara1">&#x0005b;59&#x0005d;</xref>.</p><sec id="s4a1"><title>Strengths and limitations</title><p>In our study, the data collection was prospective, before the diagnosis of AMI or CHD and equal for all participants. This ensures that the cases and the randomly selected controls are comparable <xref ref-type="bibr" rid="pone.0002533-Prentice1">&#x0005b;17&#x0005d;</xref>. For a multifactorial trait, like CHD, this provides a valid approach to evaluate the relationship between genetic factors and the risk of AMI and CHD, while taking into account co-existing and risk-modifying factors. In this study, prevalent cases of CHD were excluded from the analyses to prevent introducing bias due to potentially selective survival. The Prospect study was a population-based cohort, which makes it less susceptible to selection bias. Additional strengths were the comprehensiveness of our data and sample collection, as well as the morbidity and mortality follow-up for the entire cohort through linkage with nation-wide registries. The case-cohort design of the study combined the advantages of cohort studies (multiple outcomes and time-dependent covariates) with those of case-control analyses (fewer subjects); thus, it was more efficient than cohort studies. Classical case-control studies might be affected by selection bias since only non-fatal cases can be included, which was not the case in this study because of our endpoint definition. Moreover, we did not have misclassification of exposure (genotypes), which, when present, generally lead to a bias toward the null because we used standard laboratory protocols, performed a random double-check to detect potential genotyping errors, and had our <italic>AGT</italic> genotypes in Hardy-Weinberg equilibrium. The limitations of this study were the relatively short period of follow-up and the small number of cases. Moreover, because this cohort was exclusively composed of Dutch women, these results cannot be generalized to men or other ethnic groups, for whom the rates of the events or the allele frequency are known to differ.</p></sec></sec><sec id="s4b"><title>Meta-Analysis</title><p>The current meta-analysis, which includes new data from a prospective study in a large population-based cohort of Dutch women, represents a comprehensive evaluation of the M235T variant of the <italic>AGT</italic> gene in CHD risk. Although a pooled per-allele OR was suggestive of a modest increase in the risk of CHD of 1.08 (95&#x00025; CI, 1.01 to 1.15), the robustness of this summary estimate is uncertain. First, in the pre-specified sub-groups analyses in the meta-analysis, larger studies, those with validated genotyping quality controls, and studies that used standardized criteria for case definition did not provide strong evidence for a positive statistically significant association between the M235T variant of the <italic>AGT</italic> gene and CHD risk. Second, the meta-regression analysis revealed that the HWE violation was a significant source of the moderate to large heterogeneity in the meta-analysis. Taking violation of HWE into account in the meta-analysis decreased the overall effect (<xref ref-type="table" rid="pone-0002533-t005">Table 5</xref>). Third, the previous result was confirmed by using HWE-deviation adjusted ORs in the meta-analysis (<xref ref-type="table" rid="pone-0002533-t006">Table 6</xref>). Moreover, there was evidence for publication bias in the meta-analysis. Taken together, these findings point to a violation of HWE and publication biases as the potential explanations for the results observed in the meta-analysis.</p><p>Some aspects of the current meta-analysis need to be considered to appreciate the findings. First, it might not be very practical to adjust for violation of HWE in the studies that mentioned that the violation is not due to genotyping errors. However, in the current meta-analysis, the HWE-violated studies that were included in the pooled estimate did not provide any reason for the violation. Therefore, we performed sensitivity analyses by using HWE-adjusted ORs and corresponding variances. Thereafter, a smaller overall effect was seen under most of the genetic models. Second, the power of tests for HWE and the power to detect genotyping errors are low. Therefore, the inability to detect a deviation from the HWE does not mean that there is no deviation, nor does it rule out the presence of genotyping errors, especially for small sample sizes. Third, our meta-analysis was based on published studies and we did not have access to the original data. However, it could be possible that an association between the genotype and disease exists in certain contexts rather than in all people studied. For example, a case-control study showed that the TT genotype was associated with an increased risk of CHD and MI only in smokers <xref ref-type="bibr" rid="pone.0002533-Buraczynska1">&#x0005b;33&#x0005d;</xref>. Finally, in all meta-analyses of gene-disease association studies, the inclusion criteria of cases and controls can be a potentially confounding factor. In this meta-analysis, cases were well defined and the source of controls was not a significant source of variation. However, the advantages of this study were the large sample size of the meta-analysis of 38 studies with 13284 cases and 18722 controls, which was twice the number of studies and sample sizes that had been reported in the previous meta-analysis <xref ref-type="bibr" rid="pone.0002533-Sethi2">&#x0005b;14&#x0005d;</xref>, the exploration of potential sources of heterogeneity in the meta-analysis, and the evaluation of the association under different modes of inheritance.</p><p>Approximately 10&#x00025; of gene-disease association studies are affected by statistically significant deviation from HWE, which could result from genotyping error, chance, inbreeding, non-random mating, differential survival of marker carriers, genetic drift, population stratification, or a combination of these reasons <xref ref-type="bibr" rid="pone.0002533-Trikalinos1">&#x0005b;20&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002533-Salanti1">&#x0005b;60&#x0005d;</xref>. Of these, genotyping error could be avoided by using standard genotyping methods and performing quality assessment. It has been recommended that authors specify the quality measures for the genotyping analysis, such as the blinding of laboratory staff to the donor subjects and hypotheses being investigated, procedures for establishing duplicates, degree of reproducibility between quality control replicates, and the inspection for conformity to HWE <xref ref-type="bibr" rid="pone.0002533-Little1">&#x0005b;61&#x0005d;</xref>. In the current meta-analysis, in studies where the blinding of genotyping staff was not reported, a statistically significant increased risk of CHD was found, while those that used blinding methods did not find a significant association. Moreover, for studies without regenotyping of a random sub-sample, a significant increase in CHD risk was found, but not for studies that performed regenotyping. Although overlapping confidence intervals for before-mentioned risks indicate caution in any interpretations, no report on blinding and regenotyping can point towards an uncertainty in quality control of genotyping in these studies. However, violation of HWE, which tends to inflate the chance of a false positive association, may be the strongest indicator of genotyping error <xref ref-type="bibr" rid="pone.0002533-Xu1">&#x0005b;62&#x0005d;</xref>.</p><p>Violation of HWE cannot solely explain the observed between-study variation in gene-disease association studies. The large between-study heterogeneity presented in most meta-analyses could be due to true heterogeneity (i.e., racial differences or differences in gene-environment interactions among various populations) or bias <xref ref-type="bibr" rid="pone.0002533-Ntzani1">&#x0005b;63&#x0005d;</xref>. Bias, which could invalidate the results of the studies, should, therefore, be explored in detail. Biological plausibility, publication bias, selection bias, biased definition of cases, biased selection of controls, and population stratification should be assessed <xref ref-type="bibr" rid="pone.0002533-Ntzani1">&#x0005b;63&#x0005d;</xref>. In this meta-analysis, we found strong evidence for publication bias. This is said to occur when the chance of the publication of a smaller study increases when it shows a stronger effect. Further exploration for sources of biases among studies showed that the selection of controls was not biased. However, using different case definitions resulted in a significant difference in the risk of CHD between those studies using WHO criteria and those using clinically diagnoses of CHD. Studies using definition of cases based on coronary angiography or based on WHO criteria had the same results. Considering a multivariate model in the meta-regression results, case definition was not a significant source of bias in the meta-analysis, while the different mean age of cases and violation of HWE were significant sources of heterogeneity. Since increasing age is a risk factor for CHD and the mean age of cases in the included studies ranged from 42 to 67 years, it is more likely that the studies with older individuals would show a stronger effect and produce heterogeneity. As case-parental controls, or other family-based designs, and genomic controls, using unlinked genetic markers which have no effect on the risk of CHD, were not available to evaluate the potential problem of population stratification among the studies, we presented effect estimates by different ethnic groups. However, there is controversy about the potential importance of population stratification for genetic-association studies using unrelated subjects <xref ref-type="bibr" rid="pone.0002533-Wacholder1">&#x0005b;64&#x0005d;</xref>.</p><p>In conclusion, the present meta-analysis, including our own data, indicated that, although a weak association between the M235T variant in the <italic>AGT</italic> gene and CHD was found, the relevance of this weakly positive overall association remains uncertain because it may be due to various residual biases. Moderate to large heterogeneity was identified between studies, and violation of HWE and the mean age of cases were statistically significant sources of the observed variation.</p></sec></sec></body><back><ack><p>We are grateful to the participants of the Prospect-EPIC study. We would like to thank all field workers and laboratory technicians for their skillful contributions to the data collection.</p></ack><ref-list><title>References</title><ref id="pone.0002533-Jeunemaitre1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jeunemaitre</surname><given-names>X</given-names></name><name><surname>Soubrier</surname><given-names>F</given-names></name><name><surname>Kotelevtsev</surname><given-names>YV</given-names></name><name><surname>Lifton</surname><given-names>RP</given-names></name><name><surname>Williams</surname><given-names>CS</given-names></name><etal/></person-group><year>1992</year><article-title>Molecular basis of human hypertension: role of angiotensinogen.</article-title><source>Cell</source><volume>71</volume><fpage>169</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">1394429</pub-id></citation></ref><ref id="pone.0002533-Caulfield1"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Caulfield</surname><given-names>M</given-names></name><name><surname>Lavender</surname><given-names>P</given-names></name><name><surname>Newell-Price</surname><given-names>J</given-names></name><name><surname>Farrall</surname><given-names>M</given-names></name><name><surname>Kamdar</surname><given-names>S</given-names></name><etal/></person-group><year>1995</year><article-title>Linkage of the angiotensinogen gene locus to human essential hypertension in African Caribbeans.</article-title><source>J Clin Invest</source><volume>96</volume><fpage>687</fpage><lpage>692</lpage><pub-id pub-id-type="pmid">7635961</pub-id></citation></ref><ref id="pone.0002533-Paillard1"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paillard</surname><given-names>F</given-names></name><name><surname>Chansel</surname><given-names>D</given-names></name><name><surname>Brand</surname><given-names>E</given-names></name><name><surname>Benetos</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>F</given-names></name><etal/></person-group><year>1999</year><article-title>Genotype-phenotype relationships for the renin-angiotensin-aldosterone system in a normal population.</article-title><source>Hypertension</source><volume>34</volume><fpage>423</fpage><lpage>429</lpage><pub-id pub-id-type="pmid">10489388</pub-id></citation></ref><ref id="pone.0002533-Staessen1"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Staessen</surname><given-names>JA</given-names></name><name><surname>Kuznetsova</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>JG</given-names></name><name><surname>Emelianov</surname><given-names>D</given-names></name><name><surname>Vlietinck</surname><given-names>R</given-names></name><etal/></person-group><year>1999</year><article-title>M235T angiotensinogen gene polymorphism and cardiovascular renal risk.</article-title><source>J Hypertens</source><volume>17</volume><fpage>9</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">10100088</pub-id></citation></ref><ref id="pone.0002533-Sattar1"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sattar</surname><given-names>N</given-names></name><name><surname>Greer</surname><given-names>IA</given-names></name></person-group><year>2002</year><article-title>Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening?</article-title><source>BMJ</source><volume>325</volume><fpage>157</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">12130616</pub-id></citation></ref><ref id="pone.0002533-Ludwig1"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ludwig</surname><given-names>EH</given-names></name><name><surname>Borecki</surname><given-names>IB</given-names></name><name><surname>Ellison</surname><given-names>RC</given-names></name><name><surname>Folsom</surname><given-names>AR</given-names></name><name><surname>Heiss</surname><given-names>G</given-names></name><etal/></person-group><year>1997</year><article-title>Associations between candidate loci angiotensin-converting enzyme and angiotensinogen with coronary heart disease and myocardial infarction: the NHLBI Family Heart Study.</article-title><source>Ann Epidemiol</source><volume>7</volume><fpage>3</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">9034401</pub-id></citation></ref><ref id="pone.0002533-Olivieri1"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Olivieri</surname><given-names>O</given-names></name><name><surname>Stranieri</surname><given-names>C</given-names></name><name><surname>Girelli</surname><given-names>D</given-names></name><name><surname>Pizzolo</surname><given-names>F</given-names></name><name><surname>Grazioli</surname><given-names>S</given-names></name><etal/></person-group><year>2001</year><article-title>Homozygosity for angiotensinogen 235T variant increases the risk of myocardial infarction in patients with multi-vessel coronary artery disease.</article-title><source>J Hypertens</source><volume>19</volume><fpage>879</fpage><lpage>884</lpage><pub-id pub-id-type="pmid">11393670</pub-id></citation></ref><ref id="pone.0002533-RodriguezPerez1"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Perez</surname><given-names>JC</given-names></name><name><surname>Rodriguez-Esparragon</surname><given-names>F</given-names></name><name><surname>Hernandez-Perera</surname><given-names>O</given-names></name><name><surname>Anabitarte</surname><given-names>A</given-names></name><name><surname>Losada</surname><given-names>A</given-names></name><etal/></person-group><year>2001</year><article-title>Association of angiotensinogen M235T and A(-6)G gene polymorphisms with coronary heart disease with independence of essential hypertension: the PROCAGENE study. Prospective Cardiac Gene.</article-title><source>J Am Coll Cardiol</source><volume>37</volume><fpage>1536</fpage><lpage>1542</lpage><pub-id pub-id-type="pmid">11345362</pub-id></citation></ref><ref id="pone.0002533-Lanz1"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lanz</surname><given-names>JR</given-names></name><name><surname>Pereira</surname><given-names>AC</given-names></name><name><surname>Lemos</surname><given-names>PA</given-names></name><name><surname>Martinez</surname><given-names>E</given-names></name><name><surname>Krieger</surname><given-names>JE</given-names></name></person-group><year>2005</year><article-title>Angiotensinogen M235T polymorphism is associated with coronary artery disease severity.</article-title><source>Clin Chim Acta</source><volume>362</volume><fpage>176</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">16045904</pub-id></citation></ref><ref id="pone.0002533-Sekuri1"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sekuri</surname><given-names>C</given-names></name><name><surname>Cam</surname><given-names>FS</given-names></name><name><surname>Ercan</surname><given-names>E</given-names></name><name><surname>Tengiz</surname><given-names>I</given-names></name><name><surname>Sagcan</surname><given-names>A</given-names></name><etal/></person-group><year>2005</year><article-title>Renin-angiotensin system gene polymorphisms and premature coronary heart disease.</article-title><source>J Renin Angiotensin Aldosterone Syst</source><volume>6</volume><fpage>38</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">16088850</pub-id></citation></ref><ref id="pone.0002533-Nair1"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nair</surname><given-names>KG</given-names></name><name><surname>Shalia</surname><given-names>KK</given-names></name><name><surname>Ashavaid</surname><given-names>TF</given-names></name><name><surname>Dalal</surname><given-names>JJ</given-names></name></person-group><year>2003</year><article-title>Coronary heart disease, hypertension, and angiotensinogen gene variants in Indian population.</article-title><source>J Clin Lab Anal</source><volume>17</volume><fpage>141</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">12938141</pub-id></citation></ref><ref id="pone.0002533-Sethi1"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sethi</surname><given-names>AA</given-names></name><name><surname>Nordestgaard</surname><given-names>BG</given-names></name><name><surname>Gronholdt</surname><given-names>ML</given-names></name><name><surname>Steffensen</surname><given-names>R</given-names></name><name><surname>Jensen</surname><given-names>G</given-names></name><etal/></person-group><year>2003</year><article-title>Angiotensinogen single nucleotide polymorphisms, elevated blood pressure, and risk of cardiovascular disease.</article-title><source>Hypertension</source><volume>41</volume><fpage>1202</fpage><lpage>1211</lpage><pub-id pub-id-type="pmid">12743009</pub-id></citation></ref><ref id="pone.0002533-Tiret1"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tiret</surname><given-names>L</given-names></name><name><surname>Blanc</surname><given-names>H</given-names></name><name><surname>Ruidavets</surname><given-names>JB</given-names></name><name><surname>Arveiler</surname><given-names>D</given-names></name><name><surname>Luc</surname><given-names>G</given-names></name><etal/></person-group><year>1998</year><article-title>Gene polymorphisms of the renin-angiotensin system in relation to hypertension and parental history of myocardial infarction and stroke: the PEGASE study. Projet d'Etude des Genes de l'Hypertension Arterielle Severe a moderee Essentielle.</article-title><source>J Hypertens</source><volume>16</volume><fpage>37</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">9533415</pub-id></citation></ref><ref id="pone.0002533-Sethi2"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sethi</surname><given-names>AA</given-names></name><name><surname>Nordestgaard</surname><given-names>BG</given-names></name><name><surname>Tybjaerg-Hansen</surname><given-names>A</given-names></name></person-group><year>2003</year><article-title>Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease: a meta-analysis.</article-title><source>Arterioscler Thromb Vasc Biol</source><volume>23</volume><fpage>1269</fpage><lpage>1275</lpage><pub-id pub-id-type="pmid">12805070</pub-id></citation></ref><ref id="pone.0002533-Boker1"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boker</surname><given-names>LK</given-names></name><name><surname>van Noord</surname><given-names>PA</given-names></name><name><surname>van der Schouw</surname><given-names>YT</given-names></name><name><surname>Koot</surname><given-names>NV</given-names></name><name><surname>Bueno de Mesquita</surname><given-names>HB</given-names></name><etal/></person-group><year>2001</year><article-title>Prospect-EPIC Utrecht: study design and characteristics of the cohort population. European Prospective Investigation into Cancer and Nutrition.</article-title><source>Eur J Epidemiol</source><volume>17</volume><fpage>1047</fpage><lpage>1053</lpage><pub-id pub-id-type="pmid">12380720</pub-id></citation></ref><ref id="pone.0002533-Zafarmand1"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zafarmand</surname><given-names>MH</given-names></name><name><surname>van der Schouw</surname><given-names>YT</given-names></name><name><surname>Grobbee</surname><given-names>DE</given-names></name><name><surname>de Leeuw</surname><given-names>PW</given-names></name><name><surname>Bots</surname><given-names>ML</given-names></name></person-group><year>2008</year><article-title>T64A polymorphism in beta3-adrenergic receptor gene (ADRB3) and coronary heart disease: a case-cohort study and meta-analysis.</article-title><source>J Intern Med</source><volume>263</volume><fpage>79</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">18088254</pub-id></citation></ref><ref id="pone.0002533-Prentice1"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prentice</surname><given-names>RL</given-names></name></person-group><year>1986</year><article-title>A case-cohort design for epidemiologic cohort studies and disease prevention trials.</article-title><source>Biometrika</source><volume>73</volume><fpage>1</fpage><lpage>11</lpage></citation></ref><ref id="pone.0002533-Cheng1"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>S</given-names></name><name><surname>Grow</surname><given-names>MA</given-names></name><name><surname>Pallaud</surname><given-names>C</given-names></name><name><surname>Klitz</surname><given-names>W</given-names></name><name><surname>Erlich</surname><given-names>HA</given-names></name><etal/></person-group><year>1999</year><article-title>A multilocus genotyping assay for candidate markers of cardiovascular disease risk.</article-title><source>Genome Res</source><volume>9</volume><fpage>936</fpage><lpage>949</lpage><pub-id pub-id-type="pmid">10523522</pub-id></citation></ref><ref id="pone.0002533-OnlandMoret1"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Onland-Moret</surname><given-names>NC</given-names></name><name><surname>van der</surname><given-names>AD</given-names></name><name><surname>van der Schouw</surname><given-names>YT</given-names></name><name><surname>Buschers</surname><given-names>W</given-names></name><name><surname>Elias</surname><given-names>SG</given-names></name><etal/></person-group><year>2007</year><article-title>Analysis of case-cohort data: a comparison of different methods.</article-title><source>J Clin Epidemiol</source><volume>60</volume><fpage>350</fpage><lpage>355</lpage><pub-id pub-id-type="pmid">17346608</pub-id></citation></ref><ref id="pone.0002533-Trikalinos1"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trikalinos</surname><given-names>TA</given-names></name><name><surname>Salanti</surname><given-names>G</given-names></name><name><surname>Khoury</surname><given-names>MJ</given-names></name><name><surname>Ioannidis</surname><given-names>JP</given-names></name></person-group><year>2006</year><article-title>Impact of violations and deviations in Hardy-Weinberg equilibrium on postulated gene-disease associations.</article-title><source>Am J Epidemiol</source><volume>163</volume><fpage>300</fpage><lpage>309</lpage><pub-id pub-id-type="pmid">16410351</pub-id></citation></ref><ref id="pone.0002533-Higgins1"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Higgins</surname><given-names>JP</given-names></name><name><surname>Thompson</surname><given-names>SG</given-names></name><name><surname>Deeks</surname><given-names>JJ</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name></person-group><year>2003</year><article-title>Measuring inconsistency in meta-analyses.</article-title><source>BMJ</source><volume>327</volume><fpage>557</fpage><lpage>560</lpage><pub-id pub-id-type="pmid">12958120</pub-id></citation></ref><ref id="pone.0002533-AgerholmLarsen1"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agerholm-Larsen</surname><given-names>B</given-names></name><name><surname>Nordestgaard</surname><given-names>BG</given-names></name><name><surname>Tybjaerg-Hansen</surname><given-names>A</given-names></name></person-group><year>2000</year><article-title>ACE gene polymorphism in cardiovascular disease: meta-analyses of small and large studies in whites.</article-title><source>Arterioscler Thromb Vasc Biol</source><volume>20</volume><fpage>484</fpage><lpage>492</lpage><pub-id pub-id-type="pmid">10669647</pub-id></citation></ref><ref id="pone.0002533-Berdeli1"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berdeli</surname><given-names>A</given-names></name><name><surname>Sekuri</surname><given-names>C</given-names></name><name><surname>Sirri</surname><given-names>CF</given-names></name><name><surname>Ercan</surname><given-names>E</given-names></name><name><surname>Sagcan</surname><given-names>A</given-names></name><etal/></person-group><year>2005</year><article-title>Association between the eNOS (Glu298Asp) and the RAS genes polymorphisms and premature coronary artery disease in a Turkish population.</article-title><source>Clin Chim Acta</source><volume>351</volume><fpage>87</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">15563875</pub-id></citation></ref><ref id="pone.0002533-FernandezArcas1"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fernandez-Arcas</surname><given-names>N</given-names></name><name><surname>eguez-Lucena</surname><given-names>JL</given-names></name><name><surname>Munoz-Moran</surname><given-names>E</given-names></name><name><surname>Ruiz-Galdon</surname><given-names>M</given-names></name><name><surname>Espinosa-Caliani</surname><given-names>S</given-names></name><etal/></person-group><year>2001</year><article-title>Both alleles of the M235T polymorphism of the angiotensinogen gene can be a risk factor for myocardial infarction.</article-title><source>Clin Genet</source><volume>60</volume><fpage>52</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">11531970</pub-id></citation></ref><ref id="pone.0002533-Zee1"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zee</surname><given-names>RY</given-names></name><name><surname>Cook</surname><given-names>NR</given-names></name><name><surname>Cheng</surname><given-names>S</given-names></name><name><surname>Erlich</surname><given-names>HA</given-names></name><name><surname>Lindpaintner</surname><given-names>K</given-names></name><etal/></person-group><year>2006</year><article-title>Multi-locus candidate gene polymorphisms and risk of myocardial infarction: a population-based, prospective genetic analysis.</article-title><source>J Thromb Haemost</source><volume>4</volume><fpage>341</fpage><lpage>348</lpage><pub-id pub-id-type="pmid">16420563</pub-id></citation></ref><ref id="pone.0002533-Petrovic1"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Petrovic</surname><given-names>D</given-names></name><name><surname>Zorc</surname><given-names>M</given-names></name><name><surname>Kanic</surname><given-names>V</given-names></name><name><surname>Peterlin</surname><given-names>B</given-names></name></person-group><year>2001</year><article-title>Interaction between gene polymorphisms of renin-angiotensin system and metabolic risk factors in premature myocardial infarction.</article-title><source>Angiology</source><volume>52</volume><fpage>247</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">11330506</pub-id></citation></ref><ref id="pone.0002533-Krizanova1"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krizanova</surname><given-names>O</given-names></name><name><surname>Obdrzalkova</surname><given-names>D</given-names></name><name><surname>Polakova</surname><given-names>H</given-names></name><name><surname>Jelok</surname><given-names>I</given-names></name><name><surname>Hudecova</surname><given-names>S</given-names></name></person-group><year>1997</year><article-title>Molecular variants of the renin-angiotensin system components in the Slovak population.</article-title><source>Physiol Res</source><volume>46</volume><fpage>357</fpage><lpage>361</lpage><pub-id pub-id-type="pmid">9728481</pub-id></citation></ref><ref id="pone.0002533-Goldenberg1"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goldenberg</surname><given-names>I</given-names></name><name><surname>Moss</surname><given-names>AJ</given-names></name><name><surname>Ryan</surname><given-names>D</given-names></name><name><surname>McNitt</surname><given-names>S</given-names></name><name><surname>Eberly</surname><given-names>SW</given-names></name><etal/></person-group><year>2006</year><article-title>Polymorphism in the angiotensinogen gene, hypertension, and ethnic differences in the risk of recurrent coronary events.</article-title><source>Hypertension</source><volume>48</volume><fpage>693</fpage><lpage>699</lpage><pub-id pub-id-type="pmid">16940224</pub-id></citation></ref><ref id="pone.0002533-Sethi3"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sethi</surname><given-names>AA</given-names></name><name><surname>Tybjaerg-Hansen</surname><given-names>A</given-names></name><name><surname>Gronholdt</surname><given-names>ML</given-names></name><name><surname>Steffensen</surname><given-names>R</given-names></name><name><surname>Schnohr</surname><given-names>P</given-names></name><etal/></person-group><year>2001</year><article-title>Angiotensinogen mutations and risk for ischemic heart disease, myocardial infarction, and ischemic cerebrovascular disease. Six case-control studies from the Copenhagen City Heart Study.</article-title><source>Ann Intern Med</source><volume>134</volume><fpage>941</fpage><lpage>954</lpage><pub-id pub-id-type="pmid">11352695</pub-id></citation></ref><ref id="pone.0002533-Araujo1"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Araujo</surname><given-names>MA</given-names></name><name><surname>Goulart</surname><given-names>LR</given-names></name><name><surname>Cordeiro</surname><given-names>ER</given-names></name><name><surname>Gatti</surname><given-names>RR</given-names></name><name><surname>Menezes</surname><given-names>BS</given-names></name><etal/></person-group><year>2005</year><article-title>Genotypic interactions of renin-angiotensin system genes in myocardial infarction.</article-title><source>Int J Cardiol</source><volume>103</volume><fpage>27</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">16061119</pub-id></citation></ref><ref id="pone.0002533-Batalla1"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Batalla</surname><given-names>A</given-names></name><name><surname>Alvarez</surname><given-names>R</given-names></name><name><surname>Reguero</surname><given-names>JR</given-names></name><name><surname>Hevia</surname><given-names>S</given-names></name><name><surname>Iglesias-Cubero</surname><given-names>G</given-names></name><etal/></person-group><year>2000</year><article-title>Synergistic effect between apolipoprotein E and angiotensinogen gene polymorphisms in the risk for early myocardial infarction.</article-title><source>Clin Chem</source><volume>46</volume><fpage>1910</fpage><lpage>1915</lpage><pub-id pub-id-type="pmid">11106322</pub-id></citation></ref><ref id="pone.0002533-Bis1"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bis</surname><given-names>JC</given-names></name><name><surname>Smith</surname><given-names>NL</given-names></name><name><surname>Psaty</surname><given-names>BM</given-names></name><name><surname>Heckbert</surname><given-names>SR</given-names></name><name><surname>Edwards</surname><given-names>KL</given-names></name><etal/></person-group><year>2003</year><article-title>Angiotensinogen Met235Thr polymorphism, angiotensin-converting enzyme inhibitor therapy, and the risk of nonfatal stroke or myocardial infarction in hypertensive patients.</article-title><source>Am J Hypertens</source><volume>16</volume><fpage>1011</fpage><lpage>1017</lpage><pub-id pub-id-type="pmid">14643574</pub-id></citation></ref><ref id="pone.0002533-Buraczynska1"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buraczynska</surname><given-names>M</given-names></name><name><surname>Pijanowski</surname><given-names>Z</given-names></name><name><surname>Spasiewicz</surname><given-names>D</given-names></name><name><surname>Nowicka</surname><given-names>T</given-names></name><name><surname>Sodolski</surname><given-names>T</given-names></name><etal/></person-group><year>2003</year><article-title>Renin-angiotensin system gene polymorphisms: assessment of the risk of coronary heart disease.</article-title><source>Kardiol Pol</source><volume>58</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">14502296</pub-id></citation></ref><ref id="pone.0002533-Cong1"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cong</surname><given-names>ND</given-names></name><name><surname>Hamaguchi</surname><given-names>K</given-names></name><name><surname>Saikawa</surname><given-names>T</given-names></name><name><surname>Hara</surname><given-names>M</given-names></name><name><surname>Sakata</surname><given-names>T</given-names></name></person-group><year>1998</year><article-title>A polymorphism of angiotensinogen gene codon 174 and coronary artery disease in Japanese subjects.</article-title><source>Am J Med Sci</source><volume>316</volume><fpage>339</fpage><lpage>344</lpage><pub-id pub-id-type="pmid">9822117</pub-id></citation></ref><ref id="pone.0002533-Ermis1"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ermis</surname><given-names>C</given-names></name><name><surname>Tsai</surname><given-names>MY</given-names></name><name><surname>Hanson</surname><given-names>NQ</given-names></name><name><surname>Akar</surname><given-names>N</given-names></name><name><surname>Aras</surname><given-names>O</given-names></name></person-group><year>2002</year><article-title>Angiotensin I converting enzyme, angiotensin II type 1 receptor and angiotensinogen polymorphisms and early myocardial infarction in Turkish population.</article-title><source>Thromb Haemost</source><volume>88</volume><fpage>693</fpage><lpage>694</lpage><pub-id pub-id-type="pmid">12362249</pub-id></citation></ref><ref id="pone.0002533-Fatini1"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fatini</surname><given-names>C</given-names></name><name><surname>Abbate</surname><given-names>R</given-names></name><name><surname>Pepe</surname><given-names>G</given-names></name><name><surname>Battaglini</surname><given-names>B</given-names></name><name><surname>Gensini</surname><given-names>F</given-names></name><etal/></person-group><year>2000</year><article-title>Searching for a better assessment of the individual coronary risk profile. The role of angiotensin-converting enzyme, angiotensin II type 1 receptor and angiotensinogen gene polymorphisms.</article-title><source>Eur Heart J</source><volume>21</volume><fpage>633</fpage><lpage>638</lpage><pub-id pub-id-type="pmid">10731400</pub-id></citation></ref><ref id="pone.0002533-FernandezArcas2"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fernandez-Arcas</surname><given-names>N</given-names></name><name><surname>eguez-Lucena</surname><given-names>JL</given-names></name><name><surname>Munoz-Moran</surname><given-names>E</given-names></name><name><surname>Ruiz-Galdon</surname><given-names>M</given-names></name><name><surname>Espinosa-Caliani</surname><given-names>S</given-names></name><etal/></person-group><year>1999</year><article-title>The genotype interactions of methylenetetrahydrofolate reductase and renin-angiotensin system genes are associated with myocardial infarction.</article-title><source>Atherosclerosis</source><volume>145</volume><fpage>293</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">10488956</pub-id></citation></ref><ref id="pone.0002533-Fomicheva1"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fomicheva</surname><given-names>EV</given-names></name><name><surname>Gukova</surname><given-names>SP</given-names></name><name><surname>Larionova-Vasina</surname><given-names>VI</given-names></name><name><surname>Kovalev</surname><given-names>YR</given-names></name><name><surname>Schwartz</surname><given-names>EI</given-names></name></person-group><year>2000</year><article-title>Gene-gene interaction in the RAS system in the predisposition to myocardial infarction in elder population of St. Petersburg (Russia).</article-title><source>Mol Genet Metab</source><volume>69</volume><fpage>76</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">10655161</pub-id></citation></ref><ref id="pone.0002533-Frossard1"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frossard</surname><given-names>PM</given-names></name><name><surname>Hill</surname><given-names>SH</given-names></name><name><surname>Elshahat</surname><given-names>YI</given-names></name><name><surname>Obineche</surname><given-names>EN</given-names></name><name><surname>Bokhari</surname><given-names>AM</given-names></name><etal/></person-group><year>1998</year><article-title>Associations of angiotensinogen gene mutations with hypertension and myocardial infarction in a gulf population.</article-title><source>Clin Genet</source><volume>54</volume><fpage>285</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">9831339</pub-id></citation></ref><ref id="pone.0002533-Gardemann1"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gardemann</surname><given-names>A</given-names></name><name><surname>Stricker</surname><given-names>J</given-names></name><name><surname>Humme</surname><given-names>J</given-names></name><name><surname>Nguyen</surname><given-names>QD</given-names></name><name><surname>Katz</surname><given-names>N</given-names></name><etal/></person-group><year>1999</year><article-title>Angiotensinogen T174M and M235T gene polymorphisms are associated with the extent of coronary atherosclerosis.</article-title><source>Atherosclerosis</source><volume>145</volume><fpage>309</fpage><lpage>314</lpage><pub-id pub-id-type="pmid">10488958</pub-id></citation></ref><ref id="pone.0002533-Hooper1"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hooper</surname><given-names>WC</given-names></name><name><surname>Dowling</surname><given-names>NF</given-names></name><name><surname>Wenger</surname><given-names>NK</given-names></name><name><surname>Dilley</surname><given-names>A</given-names></name><name><surname>Ellingsen</surname><given-names>D</given-names></name><etal/></person-group><year>2002</year><article-title>Relationship of venous thromboembolism and myocardial infarction with the renin-angiotensin system in African-Americans.</article-title><source>Am J Hematol</source><volume>70</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11994975</pub-id></citation></ref><ref id="pone.0002533-Ichihara1"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ichihara</surname><given-names>S</given-names></name><name><surname>Yokota</surname><given-names>M</given-names></name><name><surname>Fujimura</surname><given-names>T</given-names></name><name><surname>Kato</surname><given-names>S</given-names></name><name><surname>Hirayama</surname><given-names>H</given-names></name><etal/></person-group><year>1997</year><article-title>Lack of association between variants of the angiotensinogen gene and the risk of coronary artery disease in middle-aged Japanese men.</article-title><source>Am Heart J</source><volume>134</volume><fpage>260</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">9313606</pub-id></citation></ref><ref id="pone.0002533-Ishigami1"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ishigami</surname><given-names>T</given-names></name><name><surname>Umemura</surname><given-names>S</given-names></name><name><surname>Iwamoto</surname><given-names>T</given-names></name><name><surname>Tamura</surname><given-names>K</given-names></name><name><surname>Hibi</surname><given-names>K</given-names></name><etal/></person-group><year>1995</year><article-title>Molecular variant of angiotensinogen gene is associated with coronary atherosclerosis.</article-title><source>Circulation</source><volume>91</volume><fpage>951</fpage><lpage>954</lpage><pub-id pub-id-type="pmid">7850980</pub-id></citation></ref><ref id="pone.0002533-Kamitani1"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kamitani</surname><given-names>A</given-names></name><name><surname>Rakugi</surname><given-names>H</given-names></name><name><surname>Higaki</surname><given-names>J</given-names></name><name><surname>Ohishi</surname><given-names>M</given-names></name><name><surname>Shi</surname><given-names>SJ</given-names></name><etal/></person-group><year>1995</year><article-title>Enhanced predictability of myocardial infarction in Japanese by combined genotype analysis.</article-title><source>Hypertension</source><volume>25</volume><fpage>950</fpage><lpage>953</lpage><pub-id pub-id-type="pmid">7737732</pub-id></citation></ref><ref id="pone.0002533-Katsuya1"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Katsuya</surname><given-names>T</given-names></name><name><surname>Koike</surname><given-names>G</given-names></name><name><surname>Yee</surname><given-names>TW</given-names></name><name><surname>Sharpe</surname><given-names>N</given-names></name><name><surname>Jackson</surname><given-names>R</given-names></name><etal/></person-group><year>1995</year><article-title>Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease.</article-title><source>Lancet</source><volume>345</volume><fpage>1600</fpage><lpage>1603</lpage><pub-id pub-id-type="pmid">7783537</pub-id></citation></ref><ref id="pone.0002533-Ko1"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>YL</given-names></name><name><surname>Ko</surname><given-names>YS</given-names></name><name><surname>Wang</surname><given-names>SM</given-names></name><name><surname>Chu</surname><given-names>PH</given-names></name><name><surname>Teng</surname><given-names>MS</given-names></name><etal/></person-group><year>1997</year><article-title>Angiotensinogen and angiotensin-I converting enzyme gene polymorphisms and the risk of coronary artery disease in Chinese.</article-title><source>Hum Genet</source><volume>100</volume><fpage>210</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">9254851</pub-id></citation></ref><ref id="pone.0002533-Methot1"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Methot</surname><given-names>J</given-names></name><name><surname>Hamelin</surname><given-names>BA</given-names></name><name><surname>Bogaty</surname><given-names>P</given-names></name><name><surname>Arsenault</surname><given-names>M</given-names></name><name><surname>Plante</surname><given-names>S</given-names></name><etal/></person-group><year>2005</year><article-title>ACE-DD genotype is associated with the occurrence of acute coronary syndrome in postmenopausal women.</article-title><source>Int J Cardiol</source><volume>105</volume><fpage>308</fpage><lpage>314</lpage><pub-id pub-id-type="pmid">16274774</pub-id></citation></ref><ref id="pone.0002533-Ortlepp1"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ortlepp</surname><given-names>JR</given-names></name><name><surname>Lauscher</surname><given-names>J</given-names></name><name><surname>Janssens</surname><given-names>U</given-names></name><name><surname>Minkenberg</surname><given-names>R</given-names></name><name><surname>Hanrath</surname><given-names>P</given-names></name><etal/></person-group><year>2002</year><article-title>Analysis of several hundred genetic polymorphisms may improve assessment of the individual genetic burden for coronary artery disease.</article-title><source>Eur J Intern Med</source><volume>13</volume><fpage>485</fpage><lpage>492</lpage><pub-id pub-id-type="pmid">12446192</pub-id></citation></ref><ref id="pone.0002533-Ranjith1"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ranjith</surname><given-names>N</given-names></name><name><surname>Pegoraro</surname><given-names>RJ</given-names></name><name><surname>Rom</surname><given-names>L</given-names></name><name><surname>Lanning</surname><given-names>PA</given-names></name><name><surname>Naidoo</surname><given-names>DP</given-names></name></person-group><year>2004</year><article-title>Renin-angiotensin system and associated gene polymorphisms in myocardial infarction in young South African Indians.</article-title><source>Cardiovasc J S Afr</source><volume>15</volume><fpage>22</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">14997233</pub-id></citation></ref><ref id="pone.0002533-Reinhardt1"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reinhardt</surname><given-names>D</given-names></name><name><surname>Sigusch</surname><given-names>HH</given-names></name><name><surname>Vogt</surname><given-names>SF</given-names></name><name><surname>Zeiss</surname><given-names>C</given-names></name><name><surname>Farker</surname><given-names>K</given-names></name><etal/></person-group><year>2000</year><article-title>A common variant of the angiotensinogen gene and the risk of coronary artery disease in a German population.</article-title><source>Pharmazie</source><volume>55</volume><fpage>69</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">10683876</pub-id></citation></ref><ref id="pone.0002533-Renner1"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Renner</surname><given-names>W</given-names></name><name><surname>Nauck</surname><given-names>M</given-names></name><name><surname>Winkelmann</surname><given-names>BR</given-names></name><name><surname>Hoffmann</surname><given-names>MM</given-names></name><name><surname>Scharnagl</surname><given-names>H</given-names></name><etal/></person-group><year>2005</year><article-title>Association of angiotensinogen haplotypes with angiotensinogen levels but not with blood pressure or coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health Study.</article-title><source>J Mol Med</source><volume>83</volume><fpage>235</fpage><lpage>239</lpage><pub-id pub-id-type="pmid">15599691</pub-id></citation></ref><ref id="pone.0002533-Sheu1"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sheu</surname><given-names>WH</given-names></name><name><surname>Lee</surname><given-names>WJ</given-names></name><name><surname>Jeng</surname><given-names>CY</given-names></name><name><surname>Young</surname><given-names>MS</given-names></name><name><surname>Ding</surname><given-names>YA</given-names></name><etal/></person-group><year>1998</year><article-title>Angiotensinogen gene polymorphism is associated with insulin resistance in nondiabetic men with or without coronary heart disease.</article-title><source>Am Heart J</source><volume>136</volume><fpage>125</fpage><lpage>131</lpage><pub-id pub-id-type="pmid">9665229</pub-id></citation></ref><ref id="pone.0002533-Tobin1"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tobin</surname><given-names>MD</given-names></name><name><surname>Braund</surname><given-names>PS</given-names></name><name><surname>Burton</surname><given-names>PR</given-names></name><name><surname>Thompson</surname><given-names>JR</given-names></name><name><surname>Steeds</surname><given-names>R</given-names></name><etal/></person-group><year>2004</year><article-title>Genotypes and haplotypes predisposing to myocardial infarction: a multilocus case-control study.</article-title><source>Eur Heart J</source><volume>25</volume><fpage>459</fpage><lpage>467</lpage><pub-id pub-id-type="pmid">15039125</pub-id></citation></ref><ref id="pone.0002533-Tsai1"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>CT</given-names></name><name><surname>Hwang</surname><given-names>JJ</given-names></name><name><surname>Ritchie</surname><given-names>MD</given-names></name><name><surname>Moore</surname><given-names>JH</given-names></name><name><surname>Chiang</surname><given-names>FT</given-names></name><etal/></person-group><year>2007</year><article-title>Renin-angiotensin system gene polymorphisms and coronary artery disease in a large angiographic cohort: detection of high order gene-gene interaction.</article-title><source>Atherosclerosis</source><volume>195</volume><fpage>172</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">17118372</pub-id></citation></ref><ref id="pone.0002533-Wenzel1"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wenzel</surname><given-names>K</given-names></name><name><surname>Blackburn</surname><given-names>A</given-names></name><name><surname>Ernst</surname><given-names>M</given-names></name><name><surname>Affeldt</surname><given-names>M</given-names></name><name><surname>Hanke</surname><given-names>R</given-names></name><etal/></person-group><year>1997</year><article-title>Relationship of polymorphisms in the renin-angiotensin system and in E-selectin of patients with early severe coronary heart disease.</article-title><source>J Mol Med</source><volume>75</volume><fpage>57</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">9020385</pub-id></citation></ref><ref id="pone.0002533-Wierzbicki1"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wierzbicki</surname><given-names>AS</given-names></name><name><surname>Lambert-Hammill</surname><given-names>M</given-names></name><name><surname>Lumb</surname><given-names>PJ</given-names></name><name><surname>Crook</surname><given-names>MA</given-names></name></person-group><year>2000</year><article-title>Renin-angiotensin system polymorphisms and coronary events in familial hypercholesterolemia.</article-title><source>Hypertension</source><volume>36</volume><fpage>808</fpage><lpage>812</lpage><pub-id pub-id-type="pmid">11082147</pub-id></citation></ref><ref id="pone.0002533-Winkelmann1"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Winkelmann</surname><given-names>BR</given-names></name><name><surname>Russ</surname><given-names>AP</given-names></name><name><surname>Nauck</surname><given-names>M</given-names></name><name><surname>Klein</surname><given-names>B</given-names></name><name><surname>Bohm</surname><given-names>BO</given-names></name><etal/></person-group><year>1999</year><article-title>Angiotensinogen M235T polymorphism is associated with plasma angiotensinogen and cardiovascular disease.</article-title><source>Am Heart J</source><volume>137</volume><fpage>698</fpage><lpage>705</lpage><pub-id pub-id-type="pmid">10097233</pub-id></citation></ref><ref id="pone.0002533-YamakawaKobayashi1"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamakawa-Kobayashi</surname><given-names>K</given-names></name><name><surname>Arinami</surname><given-names>T</given-names></name><name><surname>Hamaguchi</surname><given-names>H</given-names></name></person-group><year>1995</year><article-title>Absence of association of angiotensinogen gene T235 allele with increased risk of coronary heart disease in Japanese.</article-title><source>Lancet</source><volume>346</volume><fpage>515</fpage><pub-id pub-id-type="pmid">7637519</pub-id></citation></ref><ref id="pone.0002533-Seminara1"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seminara</surname><given-names>D</given-names></name><name><surname>Khoury</surname><given-names>MJ</given-names></name><name><surname>O'Brien</surname><given-names>TR</given-names></name><name><surname>Manolio</surname><given-names>T</given-names></name><name><surname>Gwinn</surname><given-names>ML</given-names></name><etal/></person-group><year>2007</year><article-title>The emergence of networks in human genome epidemiology: challenges and opportunities.</article-title><source>Epidemiology</source><volume>18</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17179752</pub-id></citation></ref><ref id="pone.0002533-Salanti1"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salanti</surname><given-names>G</given-names></name><name><surname>Amountza</surname><given-names>G</given-names></name><name><surname>Ntzani</surname><given-names>EE</given-names></name><name><surname>Ioannidis</surname><given-names>JP</given-names></name></person-group><year>2005</year><article-title>Hardy-Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power.</article-title><source>Eur J Hum Genet</source><volume>13</volume><fpage>840</fpage><lpage>848</lpage><pub-id pub-id-type="pmid">15827565</pub-id></citation></ref><ref id="pone.0002533-Little1"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Little</surname><given-names>J</given-names></name><name><surname>Bradley</surname><given-names>L</given-names></name><name><surname>Bray</surname><given-names>MS</given-names></name><name><surname>Clyne</surname><given-names>M</given-names></name><name><surname>Dorman</surname><given-names>J</given-names></name><etal/></person-group><year>2002</year><article-title>Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations.</article-title><source>Am J Epidemiol</source><volume>156</volume><fpage>300</fpage><lpage>310</lpage><pub-id pub-id-type="pmid">12181099</pub-id></citation></ref><ref id="pone.0002533-Xu1"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Turner</surname><given-names>A</given-names></name><name><surname>Little</surname><given-names>J</given-names></name><name><surname>Bleecker</surname><given-names>ER</given-names></name><name><surname>Meyers</surname><given-names>DA</given-names></name></person-group><year>2002</year><article-title>Positive results in association studies are associated with departure from Hardy-Weinberg equilibrium: hint for genotyping error?</article-title><source>Hum Genet</source><volume>111</volume><fpage>573</fpage><lpage>574</lpage><pub-id pub-id-type="pmid">12516594</pub-id></citation></ref><ref id="pone.0002533-Ntzani1"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ntzani</surname><given-names>EE</given-names></name><name><surname>Rizos</surname><given-names>EC</given-names></name><name><surname>Ioannidis</surname><given-names>JP</given-names></name></person-group><year>2007</year><article-title>Genetic effects versus bias for candidate polymorphisms in myocardial infarction: case study and overview of large-scale evidence.</article-title><source>Am J Epidemiol</source><volume>165</volume><fpage>973</fpage><lpage>984</lpage><pub-id pub-id-type="pmid">17293603</pub-id></citation></ref><ref id="pone.0002533-Wacholder1"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wacholder</surname><given-names>S</given-names></name><name><surname>Rothman</surname><given-names>N</given-names></name><name><surname>Caporaso</surname><given-names>N</given-names></name></person-group><year>2002</year><article-title>Counterpoint: bias from population stratification is not a major threat to the validity of conclusions from epidemiological studies of common polymorphisms and cancer.</article-title><source>Cancer Epidemiol Biomarkers Prev.</source><volume>11</volume><fpage>513</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">12050091</pub-id></citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>The first author has been supported by a grant from the Iranian Ministry of Health and Medical Education (FN12265). The Prospect-EPIC study was funded by &#x0201c;Europe Against Cancer&#x0201d; Programme of the European Commission (SANCO). There are no financial or other relationships that might lead to a conflict of interest.</p></fn></fn-group></back></article> 